,drug_name,ind_name,status,knn_approved,knn_terminated,knn_unknown,prob,label
0,l-glutamine,Short Bowel Syndrome,Approved,0,0,3,0.5,1.0
1,icosapent,Breastfeeding (mother),Approved,0,0,3,0.5,1.0
2,icosapent,Hypertriglyceridemia,Approved,0,0,3,0.5,1.0
3,cholecalciferol,"Osteoporosis, Postmenopausal",Approved,1,0,2,0.6666666666666666,1.0
4,cholecalciferol,Hypoparathyroidism,Approved,2,0,1,0.8333333333333334,1.0
5,cholecalciferol,Rickets,Approved,2,0,1,0.8333333333333334,1.0
6,cholecalciferol,Hypocalcemia,Approved,2,0,1,0.8333333333333334,1.0
7,cholecalciferol,Vitamin Deficiency,Approved,1,0,2,0.6666666666666666,1.0
8,cholecalciferol,Osteomalacia,Approved,1,0,2,0.6666666666666666,1.0
9,cholecalciferol,Vitamin D-dependent rickets,Approved,1,0,2,0.6666666666666666,1.0
10,cholecalciferol,Osteoporosis,Approved,1,0,2,0.6666666666666666,1.0
11,cholecalciferol,Hyperlipidemia,Withdrawn,0,0,3,0.5,0.0
12,cholecalciferol,"Hyperparathyroidism, Primary",Withdrawn,0,0,3,0.5,0.0
13,cholecalciferol,Hypercalcemia,Withdrawn,0,0,3,0.5,0.0
14,cholecalciferol,Osteopenia,Withdrawn,0,0,3,0.5,0.0
15,cholecalciferol,Adult Acute Myeloid Leukemia without Maturation,Terminated,0,0,3,0.5,0.0
16,cholecalciferol,adult acute myeloid leukemia with 11q23 (MLL) abnormalities,Terminated,0,0,3,0.5,0.0
17,cholecalciferol,adult acute myeloid leukemia with inv(16)(p13;q22),Terminated,0,0,3,0.5,0.0
18,cholecalciferol,adult acute myeloid leukemia with t(16;16)(p13;q22),Terminated,0,0,3,0.5,0.0
19,cholecalciferol,adult acute myeloid leukemia with t(8;21)(q22;q22),Terminated,0,0,3,0.5,0.0
20,cholecalciferol,adult acute myelomonocytic leukemia (M4),Terminated,0,0,3,0.5,0.0
21,cholecalciferol,adult erythroleukemia (M6a),Terminated,0,0,3,0.5,0.0
22,cholecalciferol,adult pure erythroid leukemia (M6b),Terminated,0,0,3,0.5,0.0
23,cholecalciferol,untreated adult acute myeloid leukemia,Terminated,0,0,3,0.5,0.0
24,cholecalciferol,adult acute megakaryoblastic leukemia (M7),Terminated,0,0,3,0.5,0.0
25,cholecalciferol,adult acute monoblastic leukemia (M5a),Terminated,0,0,3,0.5,0.0
26,cholecalciferol,adult acute monocytic leukemia (M5b),Terminated,0,0,3,0.5,0.0
27,cholecalciferol,adult acute myeloblastic leukemia with maturation (M2),Terminated,0,0,3,0.5,0.0
28,cholecalciferol,Schizophrenia,Withdrawn,0,0,3,0.5,0.0
29,cholecalciferol,Schizoaffective Disorder,Withdrawn,0,0,3,0.5,0.0
30,bortezomib,Multiple Myeloma,Approved,0,1,2,0.3333333333333333,1.0
31,bortezomib,"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse",Approved,0,0,3,0.5,1.0
32,bortezomib,Non-small cell lung cancer metastatic,Terminated,0,0,3,0.5,0.0
33,bortezomib,Non-small cell lung cancer recurrent,Terminated,0,0,3,0.5,0.0
34,bortezomib,"unspecified adult solid tumor, protocol specific",Terminated,0,0,3,0.5,0.0
35,bortezomib,adult grade III lymphomatoid granulomatosis,Terminated,0,0,3,0.5,0.0
36,bortezomib,Ki-1+ Anaplastic Large Cell Lymphoma,Terminated,0,0,3,0.5,0.0
37,bortezomib,Angioimmunoblastic Lymphadenopathy,Terminated,0,0,3,0.5,0.0
38,bortezomib,Mucosa-Associated Lymphoid Tissue Lymphoma,Terminated,0,0,3,0.5,0.0
39,bortezomib,Monocytoid B-cell lymphoma,Terminated,0,0,3,0.5,0.0
40,bortezomib,recurrent adult Burkitt's lymphoma,Terminated,0,0,3,0.5,0.0
41,bortezomib,recurrent adult diffuse large cell lymphoma,Terminated,0,0,3,0.5,0.0
42,bortezomib,Cutaneous T-cell lymphoma recurrent,Terminated,0,0,3,0.5,0.0
43,bortezomib,recurrent grade 1 follicular lymphoma,Terminated,0,0,3,0.5,0.0
44,bortezomib,recurrent grade 2 follicular lymphoma,Terminated,0,0,3,0.5,0.0
45,bortezomib,recurrent grade 3 follicular lymphoma,Terminated,0,0,3,0.5,0.0
46,bortezomib,Mantle cell lymphoma recurrent,Terminated,0,0,3,0.5,0.0
47,bortezomib,Marginal zone lymphoma recurrent,Terminated,0,0,3,0.5,0.0
48,bortezomib,Mycosis fungoides/Sezary syndrome recurrent,Terminated,0,0,3,0.5,0.0
49,bortezomib,B-cell small lymphocytic lymphoma recurrent,Terminated,0,0,3,0.5,0.0
50,bortezomib,stage III adult Burkitt's lymphoma,Terminated,0,0,3,0.5,0.0
51,bortezomib,stage III adult diffuse large cell lymphoma,Terminated,0,0,3,0.5,0.0
52,bortezomib,stage III adult diffuse mixed cell lymphoma,Terminated,0,0,3,0.5,0.0
53,bortezomib,stage III adult diffuse small cleaved cell lymphoma,Terminated,0,0,3,0.5,0.0
54,bortezomib,stage III adult Hodgkin's lymphoma,Terminated,0,0,3,0.5,0.0
55,bortezomib,stage III adult immunoblastic large cell lymphoma,Terminated,0,0,3,0.5,0.0
56,bortezomib,stage III adult lymphoblastic lymphoma,Terminated,0,0,3,0.5,0.0
57,bortezomib,Adult T-cell lymphoma/leukaemia stage III,Terminated,0,0,3,0.5,0.0
58,bortezomib,Cutaneous T-cell lymphoma stage III,Terminated,0,0,3,0.5,0.0
59,bortezomib,stage III grade 1 follicular lymphoma,Terminated,0,0,3,0.5,0.0
60,bortezomib,stage III grade 2 follicular lymphoma,Terminated,0,0,3,0.5,0.0
61,bortezomib,stage III grade 3 follicular lymphoma,Terminated,0,0,3,0.5,0.0
62,bortezomib,Mantle cell lymphoma stage III,Terminated,0,0,3,0.5,0.0
63,bortezomib,Marginal zone lymphoma stage III,Terminated,0,0,3,0.5,0.0
64,bortezomib,Mycosis fungoides/Sezary syndrome stage III,Terminated,0,0,3,0.5,0.0
65,bortezomib,B-cell small lymphocytic lymphoma stage III,Terminated,0,0,3,0.5,0.0
66,bortezomib,stage IV adult Burkitt's lymphoma,Terminated,0,0,3,0.5,0.0
67,bortezomib,stage IV adult diffuse large cell lymphoma,Terminated,0,0,3,0.5,0.0
68,bortezomib,stage IV adult diffuse mixed cell lymphoma,Terminated,0,0,3,0.5,0.0
69,bortezomib,stage IV adult diffuse small cleaved cell lymphoma,Terminated,0,0,3,0.5,0.0
70,bortezomib,stage IV adult Hodgkin's lymphoma,Terminated,0,0,3,0.5,0.0
71,bortezomib,stage IV adult immunoblastic large cell lymphoma,Terminated,0,0,3,0.5,0.0
72,bortezomib,stage IV adult lymphoblastic lymphoma,Terminated,0,0,3,0.5,0.0
73,bortezomib,Adult T-cell lymphoma/leukaemia stage IV,Terminated,0,0,3,0.5,0.0
74,bortezomib,Cutaneous T-cell lymphoma stage IV,Terminated,0,0,3,0.5,0.0
75,bortezomib,AIDS-related peripheral/systemic lymphoma,Terminated,0,0,3,0.5,0.0
76,bortezomib,stage IV grade 1 follicular lymphoma,Terminated,0,0,3,0.5,0.0
77,bortezomib,stage IV grade 2 follicular lymphoma,Terminated,0,0,3,0.5,0.0
78,bortezomib,stage IV grade 3 follicular lymphoma,Terminated,0,0,3,0.5,0.0
79,bortezomib,Mantle cell lymphoma stage IV,Terminated,0,0,3,0.5,0.0
80,bortezomib,Marginal zone lymphoma stage IV,Terminated,0,0,3,0.5,0.0
81,bortezomib,Mycosis fungoides/Sezary syndrome stage IV,Terminated,0,0,3,0.5,0.0
82,bortezomib,B-cell small lymphocytic lymphoma stage IV,Terminated,0,0,3,0.5,0.0
83,bortezomib,"unspecified adult solid tumor, protocol specific",Terminated,0,0,3,0.5,0.0
84,bortezomib,recurrent adult diffuse mixed cell lymphoma,Terminated,0,0,3,0.5,0.0
85,bortezomib,recurrent adult diffuse small cleaved cell lymphoma,Terminated,0,0,3,0.5,0.0
86,bortezomib,recurrent adult grade III lymphomatoid granulomatosis,Terminated,0,0,3,0.5,0.0
87,bortezomib,recurrent adult Hodgkin's lymphoma,Terminated,0,0,3,0.5,0.0
88,bortezomib,recurrent adult immunoblastic large cell lymphoma,Terminated,0,0,3,0.5,0.0
89,bortezomib,recurrent adult lymphoblastic lymphoma,Terminated,0,0,3,0.5,0.0
90,bortezomib,Adult T-cell lymphoma/leukaemia recurrent,Terminated,0,0,3,0.5,0.0
91,bortezomib,Malignant neoplasm of stomach,Terminated,0,0,3,0.5,0.0
92,bortezomib,Bronchioloalveolar Adenocarcinoma,Terminated,0,0,3,0.5,0.0
93,bortezomib,Malignant neoplasm of lung,Withdrawn,0,0,3,0.5,0.0
94,bortezomib,B-Cell Lymphomas,Terminated,0,0,3,0.5,0.0
95,bortezomib,Lymphoproliferative Disorders,Terminated,0,0,3,0.5,0.0
96,bortezomib,leukemia,Withdrawn,0,0,3,0.5,0.0
97,bortezomib,Relapse multiple myeloma,Withdrawn,0,0,3,0.5,0.0
98,bortezomib,"Lymphoma, Non-Hodgkin",Terminated,0,0,3,0.5,0.0
99,bortezomib,Disorder of transplanted kidney,Terminated,0,0,3,0.5,0.0
100,bortezomib,recurrent adult diffuse large cell lymphoma,Terminated,0,0,3,0.5,0.0
101,bortezomib,recurrent grade 1 follicular lymphoma,Terminated,0,0,3,0.5,0.0
102,bortezomib,recurrent grade 2 follicular lymphoma,Terminated,0,0,3,0.5,0.0
103,bortezomib,recurrent grade 3 follicular lymphoma,Terminated,0,0,3,0.5,0.0
104,bortezomib,Mantle cell lymphoma recurrent,Terminated,0,0,3,0.5,0.0
105,bortezomib,Malignant tumor of colon,Terminated,0,0,3,0.5,0.0
106,trospium,Urge Incontinence,Approved,0,0,3,0.5,1.0
107,trospium,Bladder muscle dysfunction - overactive,Approved,0,0,3,0.5,1.0
108,trospium,Increased frequency of micturition,Approved,1,0,2,0.6666666666666666,1.0
109,trospium,Urgency of micturition,Approved,1,0,2,0.6666666666666666,1.0
110,pantoprazole,Erosive esophagitis,Approved,1,0,2,0.6666666666666666,1.0
111,pantoprazole,Zollinger-Ellison syndrome,Approved,2,0,1,0.8333333333333334,1.0
112,pantoprazole,Gastroesophageal reflux disease,Approved,2,0,1,0.8333333333333334,1.0
113,pantoprazole,Multiple Endocrine Neoplasia,Approved,1,0,2,0.6666666666666666,1.0
114,pantoprazole,Peptic Ulcer,Approved,3,0,0,1.0,1.0
115,eletriptan,Migraine Disorders,Approved,3,0,0,1.0,1.0
116,pregabalin,Diabetic peripheral neuropathy,Approved,0,0,3,0.5,1.0
117,pregabalin,Fibromyalgia,Approved,0,0,3,0.5,1.0
118,pregabalin,Postherpetic neuralgia,Approved,0,0,3,0.5,1.0
119,pregabalin,Generalized Anxiety Disorder,Approved,0,0,3,0.5,1.0
120,pregabalin,Epilepsy,Terminated,2,0,1,0.8333333333333334,0.0
121,pregabalin,Herpes zoster disease,Terminated,0,0,3,0.5,0.0
122,pregabalin,Spinal Cord Injuries,Terminated,0,0,3,0.5,0.0
123,pregabalin,Pain,Terminated,0,0,3,0.5,0.0
124,pregabalin,Orofacial Pain,Terminated,0,0,3,0.5,0.0
125,pregabalin,Vulvodynia,Terminated,0,0,3,0.5,0.0
126,pregabalin,Vulvar Vestibulitis,Terminated,0,0,3,0.5,0.0
127,pregabalin,Chronic pain,Withdrawn,0,0,3,0.5,0.0
128,pregabalin,Neuralgia,Terminated,0,0,3,0.5,0.0
129,ranolazine,Angina Pectoris,Approved,0,0,3,0.5,1.0
130,ranolazine,Acute Coronary Syndrome,Terminated,0,0,3,0.5,0.0
131,ranolazine,Irritable bowel syndrome with diarrhea,Terminated,0,0,3,0.5,0.0
132,ranolazine,Diarrhoea predominant irritable bowel syndrome,Terminated,0,0,3,0.5,0.0
133,ziprasidone,Bipolar disorder in remission,Approved,0,0,3,0.5,1.0
134,ziprasidone,Schizophrenia,Approved,3,0,0,1.0,1.0
135,ziprasidone,Mixed bipolar I disorder,Approved,0,0,3,0.5,1.0
136,ziprasidone,"Bipolar affective disorder, current episode manic",Approved,0,0,3,0.5,1.0
137,ziprasidone,Schizoaffective Disorder,Terminated,0,0,3,0.5,0.0
138,ziprasidone,Bipolar Disorder,Terminated,0,0,3,0.5,0.0
139,olmesartan,Hypertensive disease,Approved,0,0,3,0.5,1.0
140,argatroban,Heparin-induced thrombocytopenia with thrombosis,Approved,0,0,3,0.5,1.0
141,travoprost,Ocular Hypertension,Approved,3,0,0,1.0,1.0
142,travoprost,"Glaucoma, Open-Angle",Approved,3,0,0,1.0,1.0
143,atomoxetine,Attention deficit hyperactivity disorder,Approved,1,0,2,0.6666666666666666,1.0
144,atomoxetine,Methamphetamine dependence,Terminated,0,0,3,0.5,0.0
145,atomoxetine,Methamphetamine abuse,Terminated,0,0,3,0.5,0.0
146,atomoxetine,alcohol sensitivity,Terminated,0,0,3,0.5,0.0
147,atomoxetine,Craving for alcohol,Terminated,0,0,3,0.5,0.0
148,atomoxetine,Mood swings,Terminated,0,0,3,0.5,0.0
149,atomoxetine,Nicotine Dependence,Suspended,0,0,3,0.5,0.0
150,tenofovir,"Hepatitis B, Chronic",Approved,0,0,3,0.5,1.0
151,tenofovir,HIV Infections,Approved,0,0,3,0.5,1.0
152,tenofovir,Hepatitis B,Terminated,0,0,3,0.5,0.0
153,tenofovir,HIV-1 infection,Terminated,0,0,3,0.5,0.0
154,tenofovir,HIV-1 infection,Withdrawn,0,0,3,0.5,0.0
155,ertapenem,Miscarriage with sepsis,Approved,0,0,3,0.5,1.0
156,ertapenem,Acute bacterial peritonitis,Approved,0,0,3,0.5,1.0
157,ertapenem,Diabetic foot infection,Approved,0,0,3,0.5,1.0
158,ertapenem,Haemophilus influenzae pneumonia,Approved,1,0,2,0.6666666666666666,1.0
159,ertapenem,Peptostreptococcus infection,Approved,0,0,3,0.5,1.0
160,ertapenem,Abdominal Abscess,Approved,1,0,2,0.6666666666666666,1.0
161,ertapenem,PYELONEPHRITIS E COLI,Approved,0,0,3,0.5,1.0
162,ertapenem,Streptococcal pneumonia,Approved,0,0,3,0.5,1.0
163,ertapenem,Intraabdominal Infections,Approved,1,0,2,0.6666666666666666,1.0
164,ertapenem,Female genital tract infection,Approved,0,0,3,0.5,1.0
165,ertapenem,Moraxella catarrhalis pneumonia,Approved,0,0,3,0.5,1.0
166,ertapenem,"Pneumonia, Bacterial",Approved,0,1,2,0.3333333333333333,1.0
167,ertapenem,Endometritis,Terminated,0,0,3,0.5,0.0
168,gefitinib,Non-Small Cell Lung Carcinoma,Approved,0,0,3,0.5,1.0
169,gefitinib,Epidermal growth factor receptor positive non-small cell lung cancer,Approved,0,0,3,0.5,1.0
170,gefitinib,Squamous cell carcinoma of the hypopharynx stage III,Terminated,0,0,3,0.5,0.0
171,gefitinib,Laryngeal squamous cell carcinoma stage III,Terminated,0,0,3,0.5,0.0
172,gefitinib,stage III squamous cell carcinoma of the lip and oral cavity,Terminated,0,0,3,0.5,0.0
173,gefitinib,Oropharyngeal squamous cell carcinoma stage III,Terminated,0,0,3,0.5,0.0
174,gefitinib,Squamous cell carcinoma of the hypopharynx stage IV,Terminated,0,0,3,0.5,0.0
175,gefitinib,Laryngeal squamous cell carcinoma stage IV,Terminated,0,0,3,0.5,0.0
176,gefitinib,stage IV squamous cell carcinoma of the lip and oral cavity,Terminated,0,0,3,0.5,0.0
177,gefitinib,stage IV squamous cell carcinoma of the oropharynx,Terminated,0,0,3,0.5,0.0
178,gefitinib,Adenocarcinoma of colon,Terminated,0,1,2,0.3333333333333333,0.0
179,gefitinib,Adenocarcinoma of rectum,Terminated,0,1,2,0.3333333333333333,0.0
180,gefitinib,Mucinous adenocarcinoma of colon,Terminated,0,1,2,0.3333333333333333,0.0
181,gefitinib,mucinous adenocarcinoma of rectum,Terminated,0,1,2,0.3333333333333333,0.0
182,gefitinib,Colon cancer recurrent,Terminated,0,1,2,0.3333333333333333,0.0
183,gefitinib,Recurrent Rectal Cancer,Terminated,0,1,2,0.3333333333333333,0.0
184,gefitinib,signet ring adenocarcinoma of the colon,Terminated,0,1,2,0.3333333333333333,0.0
185,gefitinib,signet ring adenocarcinoma of the rectum,Terminated,0,1,2,0.3333333333333333,0.0
186,gefitinib,Malignant tumor of colon,Terminated,0,1,2,0.3333333333333333,0.0
187,gefitinib,Malignant neoplasm of lung,Terminated,0,0,3,0.5,0.0
188,gefitinib,Recurrent Head and Neck Carcinoma,Terminated,0,0,3,0.5,0.0
189,gefitinib,Head and neck cancer metastatic,Terminated,0,0,3,0.5,0.0
190,gefitinib,Glioblastoma,Terminated,0,0,3,0.5,0.0
191,alfuzosin,Prostatic Hypertrophy,Approved,2,0,1,0.8333333333333334,1.0
192,alfuzosin,Benign Prostatic Hyperplasia,Terminated,0,1,2,0.3333333333333333,0.0
193,alfuzosin,Urinary Retention,Terminated,0,1,2,0.3333333333333333,0.0
194,alfuzosin,Multiple Sclerosis,Terminated,0,0,3,0.5,0.0
195,alfuzosin,Bladder dysfunction,Terminated,0,0,3,0.5,0.0
196,nitisinone,"Tyrosinemia, Type I",Approved,0,0,3,0.5,1.0
197,clobazam,Lennox-Gastaut syndrome,Approved,0,0,3,0.5,1.0
198,treprostinil,Pulmonary arterial hypertension,Approved,1,0,2,0.6666666666666666,1.0
199,treprostinil,Critical limb ischemia,Terminated,0,0,3,0.5,0.0
200,treprostinil,Peripheral Vascular Diseases,Terminated,0,0,3,0.5,0.0
201,treprostinil,Foot Ulcer,Terminated,0,0,3,0.5,0.0
202,treprostinil,Peripheral Vascular Diseases,Terminated,0,0,3,0.5,0.0
203,treprostinil,Hamman-Rich syndrome,Terminated,0,1,2,0.3333333333333333,0.0
204,treprostinil,Pulmonary Hypertension,Terminated,1,1,1,0.5,0.0
205,palonosetron,Chemotherapy-induced nausea and vomiting,Approved,3,0,0,1.0,1.0
206,palonosetron,Nausea,Terminated,0,1,2,0.3333333333333333,0.0
207,palonosetron,Vomiting,Terminated,0,1,2,0.3333333333333333,0.0
208,phenylpropanolamine,Influenza-like symptoms,Approved,2,0,1,0.8333333333333334,1.0
209,phenylpropanolamine,Allergic rhinitis (disorder),Approved,2,0,1,0.8333333333333334,1.0
210,phenylpropanolamine,"Rhinitis, Vasomotor",Approved,2,0,1,0.8333333333333334,1.0
211,phenylpropanolamine,Nasal congestion (finding),Approved,2,0,1,0.8333333333333334,1.0
212,phenylpropanolamine,Coughing,Approved,1,0,2,0.6666666666666666,1.0
213,phenylpropanolamine,Hay fever,Approved,2,0,1,0.8333333333333334,1.0
214,phenylpropanolamine,Rhinorrhea,Approved,2,0,1,0.8333333333333334,1.0
215,phenylpropanolamine,Common Cold,Approved,2,0,1,0.8333333333333334,1.0
216,phenylpropanolamine,Sneezing,Approved,1,0,2,0.6666666666666666,1.0
217,phenylpropanolamine,Allergic Conjunctivitis,Approved,2,0,1,0.8333333333333334,1.0
218,phenylpropanolamine,Sinus headache,Approved,2,0,1,0.8333333333333334,1.0
219,phenylpropanolamine,Rhinitis,Approved,2,0,1,0.8333333333333334,1.0
220,sorafenib,Renal Cell Carcinoma,Approved,0,0,3,0.5,1.0
221,sorafenib,Liver carcinoma,Approved,0,0,3,0.5,1.0
222,sorafenib,Malignant epithelial neoplasm of thyroid,Approved,0,0,3,0.5,1.0
223,sorafenib,Conventional (Clear Cell) Renal Cell Carcinoma,Terminated,0,0,3,0.5,0.0
224,sorafenib,Anaplastic thyroid carcinoma,Terminated,0,0,3,0.5,0.0
225,sorafenib,insular thyroid cancer,Terminated,0,0,3,0.5,0.0
226,sorafenib,Recurrent Thyroid Carcinoma,Terminated,0,0,3,0.5,0.0
227,sorafenib,stage III follicular thyroid cancer,Terminated,0,0,3,0.5,0.0
228,sorafenib,stage III papillary thyroid cancer,Terminated,0,0,3,0.5,0.0
229,sorafenib,stage IV follicular thyroid cancer,Terminated,0,0,3,0.5,0.0
230,sorafenib,Metastatic papillary thyroid carcinoma,Terminated,0,0,3,0.5,0.0
231,sorafenib,Anaplastic thyroid carcinoma,Terminated,0,0,3,0.5,0.0
232,sorafenib,Recurrent Thyroid Carcinoma,Terminated,0,0,3,0.5,0.0
233,sorafenib,Conventional (Clear Cell) Renal Cell Carcinoma,Terminated,0,0,3,0.5,0.0
234,sorafenib,Non-Small Cell Lung Carcinoma,Terminated,0,0,3,0.5,0.0
235,sorafenib,"unspecified adult solid tumor, protocol specific",Terminated,0,0,3,0.5,0.0
236,sorafenib,Malignant neoplasm of lung,Terminated,0,0,3,0.5,0.0
237,sorafenib,Colorectal Neoplasms,Terminated,0,0,3,0.5,0.0
238,sorafenib,Liver cell carcinoma non-resectable,Terminated,0,0,3,0.5,0.0
239,sorafenib,Hepatoma recurrent,Terminated,0,0,3,0.5,0.0
240,sorafenib,Neoplasms by Histologic Type,Terminated,0,0,3,0.5,0.0
241,sorafenib,Carcinoma,Terminated,0,0,3,0.5,0.0
242,sorafenib,Liver neoplasms,Terminated,0,0,3,0.5,0.0
243,sorafenib,Adenocarcinoma,Terminated,0,0,3,0.5,0.0
244,sorafenib,"Neoplasms, Glandular and Epithelial",Terminated,0,0,3,0.5,0.0
245,sorafenib,Malignant neoplasm of lung,Withdrawn,0,0,3,0.5,0.0
246,sorafenib,Medullary carcinoma of thyroid,Withdrawn,0,0,3,0.5,0.0
247,sorafenib,Melanoma recurrent,Withdrawn,0,0,3,0.5,0.0
248,sorafenib,malignant melanoma of skin stage III,Withdrawn,0,0,3,0.5,0.0
249,eszopiclone,Sleeplessness,Approved,3,0,0,1.0,1.0
250,miglustat,Gaucher Disease,Approved,0,0,3,0.5,1.0
251,miglustat,"Niemann-Pick Disease, Type C",Approved,0,0,3,0.5,1.0
252,entecavir,"Hepatitis B, Chronic",Approved,0,0,3,0.5,1.0
253,levothyroxine,Myxedema,Approved,1,0,2,0.6666666666666666,1.0
254,levothyroxine,Malignant neoplasm of thyroid,Approved,1,0,2,0.6666666666666666,1.0
255,levothyroxine,Hyperlipidemia,Approved,0,0,3,0.5,1.0
256,levothyroxine,Congenital Hypothyroidism,Approved,1,0,2,0.6666666666666666,1.0
257,levothyroxine,Hypothyroidism,Approved,1,0,2,0.6666666666666666,1.0
258,levothyroxine,Hashimoto Disease,Approved,0,0,3,0.5,1.0
259,levothyroxine,Goiter,Approved,1,0,2,0.6666666666666666,1.0
260,quinine,"Malaria, Falciparum",Approved,1,0,2,0.6666666666666666,1.0
261,duloxetine,Generalized Anxiety Disorder,Approved,0,0,3,0.5,1.0
262,duloxetine,Diabetic peripheral neuropathy,Approved,0,0,3,0.5,1.0
263,duloxetine,MUSCULOSKELETAL PAIN CHRONIC,Approved,0,0,3,0.5,1.0
264,duloxetine,Fibromyalgia,Approved,0,0,3,0.5,1.0
265,duloxetine,Major Depressive Disorder,Approved,1,0,2,0.6666666666666666,1.0
266,duloxetine,Female stress incontinence,Approved,0,0,3,0.5,1.0
267,duloxetine,Traumatic Brain Injury,Terminated,0,0,3,0.5,0.0
268,duloxetine,Depressive disorder,Terminated,2,0,1,0.8333333333333334,0.0
269,lenalidomide,Multiple Myeloma,Approved,1,0,2,0.6666666666666666,1.0
270,lenalidomide,"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse",Approved,0,1,2,0.3333333333333333,1.0
271,lenalidomide,Reflex Sympathetic Dystrophy,Terminated,0,1,2,0.3333333333333333,0.0
272,lenalidomide,Waldenstrom Macroglobulinemia,Terminated,0,1,2,0.3333333333333333,0.0
273,lenalidomide,Advanced cancer,Terminated,0,1,2,0.3333333333333333,0.0
274,lenalidomide,Pain,Terminated,0,1,2,0.3333333333333333,0.0
275,lenalidomide,Adult T-Cell Lymphoma/Leukemia,Terminated,0,1,2,0.3333333333333333,0.0
276,lenalidomide,Angioimmunoblastic Lymphadenopathy,Terminated,0,1,2,0.3333333333333333,0.0
277,lenalidomide,Ki-1+ Anaplastic Large Cell Lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
278,lenalidomide,leukemia,Withdrawn,0,1,2,0.3333333333333333,0.0
279,lenalidomide,Renal Cell Carcinoma,Terminated,0,1,2,0.3333333333333333,0.0
280,lenalidomide,"Lymphoma, Non-Hodgkin",Terminated,0,1,2,0.3333333333333333,0.0
281,lenalidomide,Malignant tumor of colon,Terminated,0,1,2,0.3333333333333333,0.0
282,lenalidomide,Chronic lymphocytic leukaemia stage 3,Withdrawn,0,0,3,0.5,0.0
283,lenalidomide,Chronic lymphocytic leukaemia stage 4,Withdrawn,0,0,3,0.5,0.0
284,lenalidomide,Bladder Neoplasm,Terminated,0,1,2,0.3333333333333333,0.0
285,lenalidomide,leukemia,Terminated,0,1,2,0.3333333333333333,0.0
286,lenalidomide,adult nasal type extranodal NK/T-cell lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
287,lenalidomide,Ki-1+ Anaplastic Large Cell Lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
288,lenalidomide,Angioimmunoblastic Lymphadenopathy,Terminated,0,1,2,0.3333333333333333,0.0
289,lenalidomide,Cutaneous B-Cell Non-Hodgkin Lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
290,lenalidomide,Mucosa-Associated Lymphoid Tissue Lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
291,lenalidomide,Hepatosplenic T-cell lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
292,lenalidomide,Monocytoid B-cell lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
293,lenalidomide,Peripheral T-Cell Lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
294,lenalidomide,Prolymphocytic Leukemia,Terminated,0,1,2,0.3333333333333333,0.0
295,lenalidomide,recurrent adult Burkitt's lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
296,lenalidomide,recurrent adult diffuse large cell lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
297,lenalidomide,recurrent adult diffuse mixed cell lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
298,lenalidomide,recurrent adult diffuse small cleaved cell lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
299,lenalidomide,recurrent grade 1 follicular lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
300,lenalidomide,recurrent grade 2 follicular lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
301,lenalidomide,recurrent grade 3 follicular lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
302,lenalidomide,Mantle cell lymphoma recurrent,Terminated,0,1,2,0.3333333333333333,0.0
303,lenalidomide,Marginal zone lymphoma recurrent,Terminated,0,1,2,0.3333333333333333,0.0
304,lenalidomide,Mycosis fungoides/Sezary syndrome recurrent,Terminated,0,1,2,0.3333333333333333,0.0
305,lenalidomide,B-cell small lymphocytic lymphoma recurrent,Terminated,0,1,2,0.3333333333333333,0.0
306,lenalidomide,Chronic lymphocytic leukaemia refractory,Terminated,0,1,2,0.3333333333333333,0.0
307,lenalidomide,Hairy cell leukaemia recurrent,Terminated,0,1,2,0.3333333333333333,0.0
308,lenalidomide,Small Intestinal Lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
309,lenalidomide,Splenic Marginal Zone B-Cell Lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
310,lenalidomide,T-Cell Large Granular Lymphocyte Leukemia,Terminated,0,1,2,0.3333333333333333,0.0
311,lenalidomide,Malignant lymphoma of testis,Terminated,0,1,2,0.3333333333333333,0.0
312,lenalidomide,recurrent adult grade III lymphomatoid granulomatosis,Terminated,0,1,2,0.3333333333333333,0.0
313,lenalidomide,recurrent adult immunoblastic large cell lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
314,lenalidomide,recurrent adult lymphoblastic lymphoma,Terminated,0,1,2,0.3333333333333333,0.0
315,lenalidomide,Adult T-cell lymphoma/leukaemia recurrent,Terminated,0,1,2,0.3333333333333333,0.0
316,lenalidomide,Cutaneous T-cell lymphoma recurrent,Terminated,0,1,2,0.3333333333333333,0.0
317,darifenacin,Bladder muscle dysfunction - overactive,Approved,2,0,1,0.8333333333333334,1.0
318,darifenacin,Urge Incontinence,Approved,2,0,1,0.8333333333333334,1.0
319,darifenacin,Urgency of micturition,Approved,3,0,0,1.0,1.0
320,darifenacin,Increased frequency of micturition,Approved,3,0,0,1.0,1.0
321,nitazoxanide,Giardiasis,Approved,0,0,3,0.5,1.0
322,nitazoxanide,Cryptosporidiosis,Approved,0,0,3,0.5,1.0
323,nitazoxanide,Clostridium difficile infection,Terminated,0,0,3,0.5,0.0
324,nitazoxanide,Clostridium Infections,Terminated,0,0,3,0.5,0.0
325,oxaliplatin,Metastasis from malignant tumor of colon,Approved,0,0,3,0.5,1.0
326,oxaliplatin,Colorectal Neoplasms,Terminated,0,0,3,0.5,0.0
327,oxaliplatin,"unspecified adult solid tumor, protocol specific",Terminated,0,2,1,0.16666666666666666,0.0
328,oxaliplatin,Colorectal Neoplasms,Terminated,0,0,3,0.5,0.0
329,oxaliplatin,Recurrent Rectal Cancer,Terminated,0,0,3,0.5,0.0
330,oxaliplatin,signet ring adenocarcinoma of the rectum,Terminated,0,0,3,0.5,0.0
331,oxaliplatin,Stage IIA Rectal Cancer,Terminated,0,0,3,0.5,0.0
332,oxaliplatin,Stage IIB Rectal Cancer,Terminated,0,0,3,0.5,0.0
333,oxaliplatin,Stage IIC Rectal Cancer,Terminated,0,0,3,0.5,0.0
334,oxaliplatin,Stage IIIA Rectal Cancer,Terminated,0,0,3,0.5,0.0
335,oxaliplatin,Stage IIIB Rectal Cancer,Terminated,0,0,3,0.5,0.0
336,oxaliplatin,Stage IIIC Rectal Cancer,Terminated,0,0,3,0.5,0.0
337,oxaliplatin,Stage IVA Rectal Cancer,Terminated,0,0,3,0.5,0.0
338,oxaliplatin,Stage IVB Rectal Cancer,Terminated,0,0,3,0.5,0.0
339,oxaliplatin,mucinous adenocarcinoma of rectum,Terminated,0,0,3,0.5,0.0
340,oxaliplatin,Malignant tumor of colon,Terminated,0,0,3,0.5,0.0
341,oxaliplatin,Adenocarcinoma of colon,Terminated,0,0,3,0.5,0.0
342,oxaliplatin,Adenocarcinoma of rectum,Terminated,0,0,3,0.5,0.0
343,oxaliplatin,Colon cancer recurrent,Terminated,0,0,3,0.5,0.0
344,oxaliplatin,Recurrent Rectal Cancer,Terminated,0,0,3,0.5,0.0
345,oxaliplatin,Secondary malignant neoplasm of liver,Terminated,0,0,3,0.5,0.0
346,oxaliplatin,Colon cancer recurrent,Terminated,0,0,3,0.5,0.0
347,oxaliplatin,Recurrent Rectal Cancer,Terminated,0,0,3,0.5,0.0
348,oxaliplatin,Malignant tumor of colon,Withdrawn,0,0,3,0.5,0.0
349,oxaliplatin,"unspecified adult solid tumor, protocol specific",Terminated,0,2,1,0.16666666666666666,0.0
350,oxaliplatin,Adenocarcinoma,Terminated,0,2,1,0.16666666666666666,0.0
351,oxaliplatin,Colonic Neoplasms,Terminated,0,0,3,0.5,0.0
352,oxaliplatin,Rectal Neoplasms,Terminated,0,0,3,0.5,0.0
353,oxaliplatin,Appendiceal Neoplasms,Terminated,0,0,3,0.5,0.0
354,oxaliplatin,Peritoneal Neoplasms,Terminated,0,0,3,0.5,0.0
355,oxaliplatin,Endocrine Gland Neoplasms,Terminated,0,0,3,0.5,0.0
356,oxaliplatin,Malignant tumor of colon,Terminated,0,0,3,0.5,0.0
357,oxaliplatin,Malignant tumor of colon,Terminated,0,0,3,0.5,0.0
358,oxaliplatin,Secondary malignant neoplasm of liver,Terminated,0,0,3,0.5,0.0
359,oxaliplatin,Malignant neoplasm of stomach,Suspended,0,1,2,0.3333333333333333,0.0
360,oxaliplatin,Malignant tumor of colon,Terminated,0,0,3,0.5,0.0
361,oxaliplatin,Malignant tumor of colon,Terminated,0,0,3,0.5,0.0
362,oxaliplatin,Malignant tumor of colon,Terminated,0,0,3,0.5,0.0
363,oxaliplatin,Cholangiocarcinoma,Withdrawn,0,1,2,0.3333333333333333,0.0
364,oxaliplatin,Colorectal Neoplasms,Terminated,0,0,3,0.5,0.0
365,oxaliplatin,Colorectal Neoplasms,Terminated,0,0,3,0.5,0.0
366,oxaliplatin,Colorectal Carcinoma,Withdrawn,0,0,3,0.5,0.0
367,oxaliplatin,Malignant tumor of colon,Withdrawn,0,0,3,0.5,0.0
368,oxaliplatin,Colorectal cancer metastatic,Withdrawn,0,0,3,0.5,0.0
369,oxaliplatin,Secondary malignant neoplasm of liver,Terminated,0,0,3,0.5,0.0
370,oxaliplatin,Colon cancer recurrent,Terminated,0,0,3,0.5,0.0
371,oxaliplatin,Recurrent Rectal Cancer,Terminated,0,0,3,0.5,0.0
372,oxaliplatin,Stage IVA Colon Cancer,Terminated,0,0,3,0.5,0.0
373,oxaliplatin,Stage IVA Rectal Cancer,Terminated,0,0,3,0.5,0.0
374,oxaliplatin,Stage IVB Colon Cancer,Terminated,0,0,3,0.5,0.0
375,oxaliplatin,Stage IVB Rectal Cancer,Terminated,0,0,3,0.5,0.0
376,oxaliplatin,Nasopharyngeal carcinoma,Terminated,0,0,3,0.5,0.0
377,oxaliplatin,Secondary malignant neoplasm of liver,Withdrawn,0,0,3,0.5,0.0
378,oxaliplatin,Gastric carcinoma stage IV,Terminated,0,0,3,0.5,0.0
379,oxaliplatin,Gallbladder Carcinoma,Suspended,0,0,3,0.5,0.0
380,oxaliplatin,Stage IB Esophageal Adenocarcinoma,Terminated,0,1,2,0.3333333333333333,0.0
381,oxaliplatin,Stage IIA Esophageal Adenocarcinoma,Terminated,0,1,2,0.3333333333333333,0.0
382,oxaliplatin,Stage IIB Esophageal Adenocarcinoma,Terminated,0,1,2,0.3333333333333333,0.0
383,oxaliplatin,Stage IIIA Esophageal Adenocarcinoma,Terminated,0,1,2,0.3333333333333333,0.0
384,oxaliplatin,Stage IIIB Esophageal Adenocarcinoma,Terminated,0,1,2,0.3333333333333333,0.0
385,oxaliplatin,Stage IIIC Esophageal Adenocarcinoma,Terminated,0,1,2,0.3333333333333333,0.0
386,lercanidipine,Hypertensive disease,Approved,2,0,1,0.8333333333333334,1.0
387,erlotinib,Non-Small Cell Lung Carcinoma,Approved,0,0,3,0.5,1.0
388,erlotinib,Adenocarcinoma of pancreas,Approved,0,0,3,0.5,1.0
389,erlotinib,adult primary hepatocellular carcinoma,Terminated,0,0,3,0.5,0.0
390,erlotinib,advanced adult primary liver cancer,Terminated,0,0,3,0.5,0.0
391,erlotinib,localized unresectable adult primary liver cancer,Terminated,0,0,3,0.5,0.0
392,erlotinib,Malignant neoplasm of lung,Terminated,0,0,3,0.5,0.0
393,erlotinib,Stage IA Non-Small Cell Lung Carcinoma,Terminated,0,0,3,0.5,0.0
394,erlotinib,Stage IB Non-Small Cell Lung Carcinoma,Terminated,0,0,3,0.5,0.0
395,erlotinib,Stage IIA Non-Small Cell Lung Carcinoma,Terminated,0,0,3,0.5,0.0
396,erlotinib,Stage IIB Non-Small Cell Lung Carcinoma,Terminated,0,0,3,0.5,0.0
397,erlotinib,Non-small cell lung cancer stage IIIA,Terminated,0,0,3,0.5,0.0
398,erlotinib,Metastatic malignant neoplasm to brain,Terminated,0,0,3,0.5,0.0
399,erlotinib,Non-small cell lung cancer recurrent,Terminated,0,0,3,0.5,0.0
400,erlotinib,Non-small cell lung cancer metastatic,Terminated,0,0,3,0.5,0.0
401,erlotinib,Malignant neoplasm of lung,Withdrawn,0,0,3,0.5,0.0
402,erlotinib,adult brain tumor,Terminated,0,0,3,0.5,0.0
403,erlotinib,Esophageal Neoplasms,Terminated,0,0,3,0.5,0.0
404,erlotinib,Esophageal Diseases,Terminated,0,0,3,0.5,0.0
405,erlotinib,Malignant neoplasm of lung,Terminated,0,0,3,0.5,0.0
406,erlotinib,Malignant neoplasm of lung,Terminated,0,0,3,0.5,0.0
407,erlotinib,Meningeal Carcinomatosis,Terminated,0,0,3,0.5,0.0
408,erlotinib,Neuroendocrine Tumors,Terminated,0,0,3,0.5,0.0
409,erlotinib,Adrenal Gland Neoplasms,Terminated,0,0,3,0.5,0.0
410,erlotinib,Neuroblastoma,Terminated,0,0,3,0.5,0.0
411,erlotinib,Multiple Endocrine Neoplasia,Terminated,0,0,3,0.5,0.0
412,erlotinib,Psoriasis,Withdrawn,0,0,3,0.5,0.0
413,erlotinib,Non-small cell lung cancer recurrent,Terminated,0,0,3,0.5,0.0
414,erlotinib,Non-small cell lung cancer metastatic,Terminated,0,0,3,0.5,0.0
415,erlotinib,Squamous cell carcinoma,Terminated,0,0,3,0.5,0.0
416,erlotinib,Ependymoma,Terminated,0,0,3,0.5,0.0
417,erlotinib,recurrent metastatic squamous neck cancer with occult primary,Withdrawn,0,0,3,0.5,0.0
418,erlotinib,Recurrent Salivary Gland Cancer,Withdrawn,0,0,3,0.5,0.0
419,erlotinib,Squamous cell carcinoma of the hypopharynx recurrent,Withdrawn,0,0,3,0.5,0.0
420,erlotinib,Laryngeal squamous cell carcinoma recurrent,Withdrawn,0,0,3,0.5,0.0
421,erlotinib,recurrent squamous cell carcinoma of the lip and oral cavity,Withdrawn,0,0,3,0.5,0.0
422,erlotinib,Oropharyngeal squamous cell carcinoma recurrent,Withdrawn,0,0,3,0.5,0.0
423,erlotinib,recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity,Withdrawn,0,0,3,0.5,0.0
424,erlotinib,Laryngeal verrucous carcinoma recurrent,Withdrawn,0,0,3,0.5,0.0
425,erlotinib,Verrucous carcinoma of the oral cavity recurrent,Withdrawn,0,0,3,0.5,0.0
426,erlotinib,squamous cell carcinoma of salivary gland,Withdrawn,0,0,3,0.5,0.0
427,erlotinib,Non-small cell lung cancer recurrent,Suspended,0,0,3,0.5,0.0
428,erlotinib,Non-small cell lung cancer metastatic,Suspended,0,0,3,0.5,0.0
429,erlotinib,Non-small cell lung cancer recurrent,Withdrawn,0,0,3,0.5,0.0
430,erlotinib,Non-small cell lung cancer metastatic,Withdrawn,0,0,3,0.5,0.0
431,erlotinib,HIV Infections,Terminated,0,0,3,0.5,0.0
432,bosentan,Pulmonary arterial hypertension,Approved,0,0,3,0.5,1.0
433,bosentan,Pulmonary Hypertension,Approved,0,0,3,0.5,1.0
434,bosentan,Scleroderma,Approved,0,0,3,0.5,1.0
435,bosentan,Persistent Fetal Circulation Syndrome,Terminated,0,0,3,0.5,0.0
436,tigecycline,Complicated appendicitis,Approved,0,0,3,0.5,1.0
437,tigecycline,Haemophilus influenzae pneumonia,Approved,2,0,1,0.8333333333333334,1.0
438,tigecycline,Abdominal Abscess,Approved,0,0,3,0.5,1.0
439,tigecycline,Intraabdominal Infections,Approved,1,0,2,0.6666666666666666,1.0
440,tigecycline,Legionella pneumophila pneumonia,Approved,0,0,3,0.5,1.0
441,tigecycline,Dialysis Catheter Infection,Terminated,0,0,3,0.5,0.0
442,voriconazole,Fusariosis,Approved,1,0,2,0.6666666666666666,1.0
443,voriconazole,Systemic candidiasis,Approved,1,0,2,0.6666666666666666,1.0
444,voriconazole,Candidiasis of the esophagus,Approved,1,0,2,0.6666666666666666,1.0
445,voriconazole,Invasive Pulmonary Aspergillosis,Approved,1,0,2,0.6666666666666666,1.0
446,voriconazole,Candidemia,Approved,1,0,2,0.6666666666666666,1.0
447,voriconazole,Invasive aspergillosis,Terminated,0,0,3,0.5,0.0
448,voriconazole,Candidiasis,Terminated,0,0,3,0.5,0.0
449,voriconazole,Aspergillosis,Withdrawn,1,0,2,0.6666666666666666,0.0
450,voriconazole,Neuroaspergillosis,Withdrawn,0,0,3,0.5,0.0
451,thiopental,Epilepsy,Approved,3,0,0,1.0,1.0
452,thiopental,Pseudotumor Cerebri,Approved,0,0,3,0.5,1.0
453,linezolid,Streptococcus pyogenes infection,Approved,0,0,3,0.5,1.0
454,linezolid,Staphylococcus aureus infection,Approved,0,0,3,0.5,1.0
455,linezolid,Staphylococcal Pneumonia,Approved,0,0,3,0.5,1.0
456,linezolid,Bacteremia,Terminated,0,0,3,0.5,0.0
457,linezolid,Gram-Positive Bacterial Infections,Terminated,0,0,3,0.5,0.0
458,linezolid,"Skin Diseases, Infectious",Terminated,0,0,3,0.5,0.0
459,imatinib,"Leukemia, Myeloid, Accelerated Phase",Approved,0,0,3,0.5,1.0
460,imatinib,"Mastocytosis, Systemic",Approved,0,0,3,0.5,1.0
461,imatinib,"Leukemia, Myeloid, Chronic-Phase",Approved,0,0,3,0.5,1.0
462,imatinib,Blast Phase,Approved,0,0,3,0.5,1.0
463,imatinib,Philadelphia chromosome positive chronic myelogenous leukemia,Approved,0,0,3,0.5,1.0
464,imatinib,Chronic eosinophilic leukemia,Approved,0,0,3,0.5,1.0
465,imatinib,Philadelphia chromosome-positive acute lymphoblastic leukemia,Approved,0,0,3,0.5,1.0
466,imatinib,Dermatofibrosarcoma Protuberans,Approved,0,0,3,0.5,1.0
467,imatinib,Idiopathic Hypereosinophilic Syndrome,Approved,0,0,3,0.5,1.0
468,imatinib,Gastrointestinal Stromal Tumors,Approved,0,0,3,0.5,1.0
469,imatinib,leukemia,Terminated,0,0,3,0.5,0.0
470,imatinib,leukemia,Terminated,0,0,3,0.5,0.0
471,imatinib,chronic myelogenous leukemia in relapse,Terminated,0,0,3,0.5,0.0
472,imatinib,Chronic myeloproliferative disorder,Terminated,0,0,3,0.5,0.0
473,imatinib,leukemia,Terminated,0,0,3,0.5,0.0
474,imatinib,Choroidal retinal neovascularization,Withdrawn,0,0,3,0.5,0.0
475,imatinib,Choroidal Neovascularization,Withdrawn,0,0,3,0.5,0.0
476,imatinib,Metastatic melanoma,Terminated,0,0,3,0.5,0.0
477,imatinib,leukemia,Terminated,0,0,3,0.5,0.0
478,imatinib,Malignant Peripheral Nerve Sheath Tumor,Terminated,0,0,3,0.5,0.0
479,imatinib,Pulmonary Hypertension,Terminated,0,0,3,0.5,0.0
480,imatinib,Solid tumour,Terminated,0,1,2,0.3333333333333333,0.0
481,imatinib,leukemia,Terminated,0,0,3,0.5,0.0
482,imatinib,recurrent adult acute lymphoblastic leukemia,Terminated,0,0,3,0.5,0.0
483,imatinib,Scleroderma,Terminated,0,0,3,0.5,0.0
484,imatinib,Pulmonary Hypertension,Withdrawn,0,0,3,0.5,0.0
485,clofarabine,Acute lymphocytic leukemia,Approved,1,0,2,0.6666666666666666,1.0
486,clofarabine,leukemia,Terminated,0,2,1,0.16666666666666666,0.0
487,clofarabine,Multiple Myeloma,Terminated,0,1,2,0.3333333333333333,0.0
488,clofarabine,leukemia,Terminated,0,2,1,0.16666666666666666,0.0
489,clofarabine,leukemia,Terminated,0,2,1,0.16666666666666666,0.0
490,clofarabine,Hodgkin Disease,Terminated,0,1,2,0.3333333333333333,0.0
491,clofarabine,Multiple Myeloma,Terminated,0,1,2,0.3333333333333333,0.0
492,clofarabine,adult acute myeloid leukemia in remission,Terminated,0,2,1,0.16666666666666666,0.0
493,clofarabine,adult acute myeloid leukemia with 11q23 (MLL) abnormalities,Terminated,0,2,1,0.16666666666666666,0.0
494,clofarabine,adult acute myeloid leukemia with inv(16)(p13;q22),Terminated,0,2,1,0.16666666666666666,0.0
495,clofarabine,adult acute myeloid leukemia with t(15;17)(q22;q12),Terminated,0,2,1,0.16666666666666666,0.0
496,clofarabine,adult acute myeloid leukemia with t(16;16)(p13;q22),Terminated,0,2,1,0.16666666666666666,0.0
497,clofarabine,adult acute myeloid leukemia with t(8;21)(q22;q22),Terminated,0,2,1,0.16666666666666666,0.0
498,clofarabine,recurrent adult acute myeloid leukemia,Terminated,0,2,1,0.16666666666666666,0.0
499,clofarabine,"Leukemia, Myelocytic, Acute",Withdrawn,1,1,1,0.5,0.0
500,clofarabine,"Neoplasm, Residual",Terminated,0,1,2,0.3333333333333333,0.0
501,clofarabine,"Histiocytosis, Langerhans-Cell",Withdrawn,0,0,3,0.5,0.0
502,clofarabine,"Leukemia, Myelocytic, Acute",Terminated,1,1,1,0.5,0.0
503,docosanol,Herpes Labialis,Approved,0,0,3,0.5,1.0
504,pemetrexed,Malignant Pleural Mesothelioma,Approved,0,0,3,0.5,1.0
505,pemetrexed,Non-Small Cell Lung Carcinoma,Approved,1,0,2,0.6666666666666666,1.0
506,pemetrexed,Malignant neoplasm of lung,Terminated,0,2,1,0.16666666666666666,0.0
507,pemetrexed,Lung Neoplasms,Terminated,0,0,3,0.5,0.0
508,pemetrexed,Malignant neoplasm of lung,Terminated,0,2,1,0.16666666666666666,0.0
509,pemetrexed,Esophageal Neoplasms,Terminated,0,0,3,0.5,0.0
510,pemetrexed,Malignant neoplasm of lung,Terminated,0,2,1,0.16666666666666666,0.0
511,pemetrexed,Malignant neoplasm of lung,Terminated,0,2,1,0.16666666666666666,0.0
512,pemetrexed,Malignant neoplasm of lung,Terminated,0,2,1,0.16666666666666666,0.0
513,pemetrexed,Primary central nervous system lymphoma,Withdrawn,0,0,3,0.5,0.0
514,pemetrexed,Mesothelioma malignant advanced,Withdrawn,0,0,3,0.5,0.0
515,pemetrexed,"Epithelioid mesothelioma, malignant",Withdrawn,0,0,3,0.5,0.0
516,pemetrexed,Mesothelioma malignant recurrent,Withdrawn,0,0,3,0.5,0.0
517,pemetrexed,Sarcomatoid Mesothelioma,Withdrawn,0,0,3,0.5,0.0
518,pemetrexed,Colorectal cancer metastatic,Terminated,0,1,2,0.3333333333333333,0.0
519,pemetrexed,Small cell carcinoma of lung,Terminated,0,0,3,0.5,0.0
520,pemetrexed,Non-small cell lung cancer stage III,Withdrawn,0,1,2,0.3333333333333333,0.0
521,pemetrexed,Non-small cell lung cancer recurrent,Withdrawn,0,0,3,0.5,0.0
522,pemetrexed,Non-small cell lung cancer metastatic,Withdrawn,0,1,2,0.3333333333333333,0.0
523,acamprosate,"Alcoholic Intoxication, Chronic",Approved,1,0,2,0.6666666666666666,1.0
524,aprepitant,Chemotherapy-induced nausea and vomiting,Approved,3,0,0,1.0,1.0
525,aprepitant,Nausea,Suspended,0,1,2,0.3333333333333333,0.0
526,aprepitant,Vomiting,Suspended,0,1,2,0.3333333333333333,0.0
527,galantamine,Alzheimer's Disease,Approved,1,0,2,0.6666666666666666,1.0
528,galantamine,Traumatic Brain Injury,Terminated,0,0,3,0.5,0.0
529,eplerenone,Hypertensive disease,Approved,3,0,0,1.0,1.0
530,eplerenone,Ascites,Withdrawn,1,0,2,0.6666666666666666,0.0
531,ibandronate,"Osteoporosis, Postmenopausal",Approved,0,0,3,0.5,1.0
532,ibandronate,Hypercalcemia,Approved,0,0,3,0.5,1.0
533,apomorphine,Parkinson Disease,Approved,1,0,2,0.6666666666666666,1.0
534,nateglinide,"Diabetes Mellitus, Non-Insulin-Dependent",Approved,3,0,0,1.0,1.0
535,esomeprazole,Erosive esophagitis,Approved,2,0,1,0.8333333333333334,1.0
536,esomeprazole,Zollinger-Ellison syndrome,Approved,3,0,0,1.0,1.0
537,esomeprazole,Peptic Esophagitis,Approved,2,0,1,0.8333333333333334,1.0
538,esomeprazole,Gastroesophageal reflux disease,Approved,3,0,0,1.0,1.0
539,esomeprazole,Peptic Ulcer,Approved,2,0,1,0.8333333333333334,1.0
540,esomeprazole,Nausea,Terminated,0,1,2,0.3333333333333333,0.0
541,esomeprazole,Laryngeal Diseases,Withdrawn,0,1,2,0.3333333333333333,0.0
542,esomeprazole,Cystic Fibrosis,Terminated,0,1,2,0.3333333333333333,0.0
543,epinastine,Itching of eye,Approved,1,0,2,0.6666666666666666,1.0
544,epinastine,Allergic Conjunctivitis,Approved,3,0,0,1.0,1.0
545,oxcarbazepine,Epilepsy characterized by intractable complex partial seizures,Approved,3,0,0,1.0,1.0
546,oxcarbazepine,"Epilepsies, Partial",Approved,2,0,1,0.8333333333333334,1.0
547,oxcarbazepine,Simple Partial Seizures,Approved,2,0,1,0.8333333333333334,1.0
548,meloxicam,Rheumatoid Arthritis,Approved,1,0,2,0.6666666666666666,1.0
549,meloxicam,Degenerative polyarthritis,Approved,0,0,3,0.5,1.0
550,tadalafil,Pulmonary Hypertension,Approved,0,0,3,0.5,1.0
551,tadalafil,Erectile dysfunction,Approved,1,0,2,0.6666666666666666,1.0
552,tadalafil,Prostatic Hypertrophy,Approved,1,0,2,0.6666666666666666,1.0
553,tadalafil,Priapism,Terminated,0,0,3,0.5,0.0
554,tadalafil,Multiple Myeloma,Terminated,0,0,3,0.5,0.0
555,mifepristone,Unspecified Abortion,Approved,0,0,3,0.5,1.0
556,mifepristone,"Affective Disorders, Psychotic",Terminated,0,0,3,0.5,0.0
557,mifepristone,Pituitary-dependent Cushing's disease,Withdrawn,0,0,3,0.5,0.0
558,vardenafil,Erectile dysfunction,Approved,1,0,2,0.6666666666666666,1.0
559,vardenafil,Cystic Fibrosis,Suspended,0,0,3,0.5,0.0
560,conivaptan,Hyponatremia,Approved,0,0,3,0.5,1.0
561,guaifenesin,Headache Disorders,Approved,2,0,1,0.8333333333333334,1.0
562,guaifenesin,Fever,Approved,2,0,1,0.8333333333333334,1.0
563,guaifenesin,Rhinitis,Approved,3,0,0,1.0,1.0
564,guaifenesin,Common Cold,Approved,3,0,0,1.0,1.0
565,guaifenesin,Influenza-like symptoms,Approved,2,0,1,0.8333333333333334,1.0
566,guaifenesin,Allergic rhinitis (disorder),Approved,3,0,0,1.0,1.0
567,guaifenesin,Nasal congestion (finding),Approved,3,0,0,1.0,1.0
568,guaifenesin,Rhinorrhea,Approved,3,0,0,1.0,1.0
569,guaifenesin,Sinus headache,Approved,0,0,3,0.5,1.0
570,guaifenesin,Coughing,Approved,3,0,0,1.0,1.0
571,emtricitabine,HIV Infections,Approved,3,0,0,1.0,1.0
572,emtricitabine,HIV-1 infection,Withdrawn,0,1,2,0.3333333333333333,0.0
573,bimatoprost,"Glaucoma, Open-Angle",Approved,3,0,0,1.0,1.0
574,bimatoprost,Ocular Hypertension,Approved,3,0,0,1.0,1.0
575,bimatoprost,Hypertrichosis of eyelid,Approved,0,0,3,0.5,1.0
576,tinidazole,Acute amebiasis,Approved,1,0,2,0.6666666666666666,1.0
577,tinidazole,Trichomonas Infections,Approved,1,0,2,0.6666666666666666,1.0
578,tinidazole,Bacterial Vaginosis,Approved,1,0,2,0.6666666666666666,1.0
579,tinidazole,"Liver Abscess, Amebic",Approved,1,0,2,0.6666666666666666,1.0
580,tinidazole,Giardiasis,Approved,1,0,2,0.6666666666666666,1.0
581,almotriptan,Migraine Disorders,Approved,3,0,0,1.0,1.0
582,tipranavir,HIV Infections,Approved,3,0,0,1.0,1.0
583,bromfenac,Pain,Approved,1,0,2,0.6666666666666666,1.0
584,desloratadine,Chronic idiopathic urticaria,Approved,0,0,3,0.5,1.0
585,desloratadine,"Rhinitis, Vasomotor",Approved,2,0,1,0.8333333333333334,1.0
586,desloratadine,Hay fever,Approved,2,0,1,0.8333333333333334,1.0
587,desloratadine,Sneezing,Approved,2,0,1,0.8333333333333334,1.0
588,desloratadine,Allergic Conjunctivitis,Approved,3,0,0,1.0,1.0
589,desloratadine,Common Cold,Approved,2,0,1,0.8333333333333334,1.0
590,desloratadine,Nasal congestion (finding),Approved,2,0,1,0.8333333333333334,1.0
591,desloratadine,Rhinorrhea,Approved,3,0,0,1.0,1.0
592,desloratadine,Allergic rhinitis (disorder),Approved,3,0,0,1.0,1.0
593,desloratadine,Allergic urticaria,Approved,0,0,3,0.5,1.0
594,alosetron,Irritable bowel syndrome with diarrhea,Approved,0,0,3,0.5,1.0
595,alosetron,Diarrhoea predominant irritable bowel syndrome,Approved,0,0,3,0.5,1.0
596,ezetimibe,"Hyperlipidemia, Familial Combined",Approved,2,0,1,0.8333333333333334,1.0
597,ezetimibe,Familial hypercholesterolemia - homozygous,Approved,0,0,3,0.5,1.0
598,ezetimibe,Hypercholesterolemia,Approved,2,0,1,0.8333333333333334,1.0
599,ezetimibe,Familial hypercholesterolemia - heterozygous,Approved,2,0,1,0.8333333333333334,1.0
600,ezetimibe,Hyperlipidemia,Approved,2,0,1,0.8333333333333334,1.0
601,ezetimibe,Sitosterolemia,Approved,0,0,3,0.5,1.0
602,ezetimibe,"Lipid Metabolism, Inborn Errors",Terminated,0,0,3,0.5,0.0
603,ezetimibe,Dyslipidemias,Terminated,0,0,3,0.5,0.0
604,ezetimibe,Diabetes Mellitus,Terminated,0,0,3,0.5,0.0
605,ezetimibe,Atherosclerosis,Terminated,0,0,3,0.5,0.0
606,ezetimibe,Non-alcoholic Fatty Liver Disease,Terminated,0,0,3,0.5,0.0
607,ramelteon,Initial insomnia,Approved,1,0,2,0.6666666666666666,1.0
608,formoterol,Intrinsic asthma,Approved,0,0,3,0.5,1.0
609,formoterol,Pulmonary Emphysema,Approved,2,0,1,0.8333333333333334,1.0
610,formoterol,Allergic asthma,Approved,0,0,3,0.5,1.0
611,formoterol,Chronic Obstructive Airway Disease,Terminated,0,0,3,0.5,0.0
612,rivastigmine,Alzheimer's Disease,Approved,1,0,2,0.6666666666666666,1.0
613,rivastigmine,Dementia associated with Parkinson's Disease,Approved,0,0,3,0.5,1.0
614,frovatriptan,Migraine Disorders,Approved,3,0,0,1.0,1.0
615,balsalazide,Ulcerative Colitis,Approved,2,0,1,0.8333333333333334,1.0
616,gatifloxacin,Acute exacerbation of chronic bronchitis,Approved,3,0,0,1.0,1.0
617,gatifloxacin,Moraxella catarrhalis pneumonia,Approved,2,0,1,0.8333333333333334,1.0
618,gatifloxacin,Bacterial conjunctivitis,Approved,2,0,1,0.8333333333333334,1.0
619,gatifloxacin,Legionella pneumophila pneumonia,Approved,1,0,2,0.6666666666666666,1.0
620,gatifloxacin,Escherichia coli urinary tract infection,Approved,1,0,2,0.6666666666666666,1.0
621,gatifloxacin,Streptococcal pneumonia,Approved,2,0,1,0.8333333333333334,1.0
622,gatifloxacin,Chlamydial pneumonia,Approved,2,0,1,0.8333333333333334,1.0
623,gatifloxacin,Acute gonococcal urethritis,Approved,1,0,2,0.6666666666666666,1.0
624,gatifloxacin,Haemophilus influenzae pneumonia,Approved,2,0,1,0.8333333333333334,1.0
625,gatifloxacin,Staphylococcal Pneumonia,Approved,2,0,1,0.8333333333333334,1.0
626,gatifloxacin,Gonorrhea of rectum,Approved,1,0,2,0.6666666666666666,1.0
627,gatifloxacin,PYELONEPHRITIS E COLI,Approved,1,0,2,0.6666666666666666,1.0
628,gatifloxacin,Staphylococcus aureus infection,Approved,2,0,1,0.8333333333333334,1.0
629,gatifloxacin,Acute gonococcal cervicitis,Approved,1,0,2,0.6666666666666666,1.0
630,gatifloxacin,"Pneumonia, Bacterial",Approved,2,0,1,0.8333333333333334,1.0
631,gatifloxacin,Mycoplasma pneumonia,Approved,2,0,1,0.8333333333333334,1.0
632,gatifloxacin,Klebsiella cystitis,Approved,1,0,2,0.6666666666666666,1.0
633,gatifloxacin,Haemophilus parainfluenzae pneumonia,Approved,1,0,2,0.6666666666666666,1.0
634,gatifloxacin,Proteus urinary tract infection,Approved,1,0,2,0.6666666666666666,1.0
635,lubiprostone,Chronic idiopathic constipation,Approved,0,0,3,0.5,1.0
636,lubiprostone,Irritable bowel syndrome characterized by constipation,Approved,0,0,3,0.5,1.0
637,melatonin,Sleep Initiation and Maintenance Disorders,Approved,0,0,3,0.5,1.0
638,melatonin,Depressive disorder,Terminated,0,0,3,0.5,0.0
639,melatonin,"ENCEPHALOPATHY, HYPOXIC-ISCHEMIC, NEWBORN",Withdrawn,0,0,3,0.5,0.0
640,cefditoren,Streptococcal tonsillitis,Approved,0,0,3,0.5,1.0
641,cefditoren,Streptococcus pyogenes infection,Approved,2,0,1,0.8333333333333334,1.0
642,cefditoren,"Pneumonia, Bacterial",Approved,2,0,1,0.8333333333333334,1.0
643,cefditoren,Acute exacerbation of chronic bronchitis,Approved,0,0,3,0.5,1.0
644,cefditoren,Streptococcal pneumonia,Approved,0,0,3,0.5,1.0
645,cefditoren,Haemophilus parainfluenzae pneumonia,Approved,2,0,1,0.8333333333333334,1.0
646,cefditoren,Staphylococcus aureus infection,Approved,1,0,2,0.6666666666666666,1.0
647,cefditoren,Haemophilus influenzae pneumonia,Approved,3,0,0,1.0,1.0
648,cefditoren,Moraxella catarrhalis pneumonia,Approved,0,0,3,0.5,1.0
649,atazanavir,HIV Infections,Approved,3,0,0,1.0,1.0
650,vigabatrin,Epilepsy characterized by intractable complex partial seizures,Approved,2,0,1,0.8333333333333334,1.0
651,vigabatrin,West Syndrome,Approved,0,0,3,0.5,1.0
652,vigabatrin,Cocaine Dependence,Terminated,0,0,3,0.5,0.0
653,vigabatrin,"Alcoholic Intoxication, Chronic",Terminated,0,0,3,0.5,0.0
654,vigabatrin,Cocaine Dependence,Terminated,0,0,3,0.5,0.0
655,iloprost,Pulmonary arterial hypertension,Approved,1,0,2,0.6666666666666666,1.0
656,iloprost,Systemic Scleroderma,Terminated,0,0,3,0.5,0.0
657,iloprost,Chronic left ventricular failure,Withdrawn,0,0,3,0.5,0.0
658,iloprost,Pulmonary Hypertension,Withdrawn,1,0,2,0.6666666666666666,0.0
659,rosuvastatin,Familial hypercholesterolemia - heterozygous,Approved,3,0,0,1.0,1.0
660,rosuvastatin,Cerebrovascular accident,Approved,2,0,1,0.8333333333333334,1.0
661,rosuvastatin,"Hyperlipidemia, Familial Combined",Approved,3,0,0,1.0,1.0
662,rosuvastatin,Familial hypercholesterolemia - homozygous,Approved,2,0,1,0.8333333333333334,1.0
663,rosuvastatin,Arteriosclerosis,Approved,3,0,0,1.0,1.0
664,rosuvastatin,Hypercholesterolemia,Approved,3,0,0,1.0,1.0
665,rosuvastatin,Hypertriglyceridemia,Approved,2,0,1,0.8333333333333334,1.0
666,rosuvastatin,Hyperlipoproteinemia Type III,Approved,2,0,1,0.8333333333333334,1.0
667,rosuvastatin,Malignant tumor of colon,Terminated,0,0,3,0.5,0.0
668,rosuvastatin,Precancerous Conditions,Terminated,0,0,3,0.5,0.0
669,rosuvastatin,Influenza due to Influenza A virus subtype H1N1,Terminated,0,0,3,0.5,0.0
670,dutasteride,Prostatic Hypertrophy,Approved,3,0,0,1.0,1.0
671,dutasteride,Benign Prostatic Hyperplasia,Terminated,0,2,1,0.16666666666666666,0.0
672,dutasteride,Adenocarcinoma of prostate,Withdrawn,0,0,3,0.5,0.0
673,proguanil,"Malaria, Falciparum",Approved,0,0,3,0.5,1.0
674,sertaconazole,Tinea Pedis,Approved,2,0,1,0.8333333333333334,1.0
675,gemifloxacin,Pneumonia due to Klebsiella pneumoniae,Approved,0,0,3,0.5,1.0
676,gemifloxacin,Acute bacterial bronchitis,Approved,0,0,3,0.5,1.0
677,gemifloxacin,Mycoplasma pneumonia,Approved,2,0,1,0.8333333333333334,1.0
678,gemifloxacin,"Pneumonia, Bacterial",Approved,0,0,3,0.5,1.0
679,gemifloxacin,Moraxella catarrhalis pneumonia,Approved,2,0,1,0.8333333333333334,1.0
680,gemifloxacin,Haemophilus influenzae pneumonia,Approved,2,0,1,0.8333333333333334,1.0
681,gemifloxacin,Chlamydial pneumonia,Approved,2,0,1,0.8333333333333334,1.0
682,gemifloxacin,Acute exacerbation of chronic bronchitis,Approved,0,0,3,0.5,1.0
683,gemifloxacin,Streptococcal pneumonia,Approved,0,0,3,0.5,1.0
684,escitalopram,Major Depressive Disorder,Approved,1,0,2,0.6666666666666666,1.0
685,escitalopram,Generalized Anxiety Disorder,Approved,1,0,2,0.6666666666666666,1.0
686,zopiclone,Sleeplessness,Approved,3,0,0,1.0,1.0
687,aripiprazole,Bipolar disorder in remission,Approved,1,0,2,0.6666666666666666,1.0
688,aripiprazole,Autistic Disorder,Approved,1,0,2,0.6666666666666666,1.0
689,aripiprazole,Mixed bipolar I disorder,Approved,1,0,2,0.6666666666666666,1.0
690,aripiprazole,Schizophrenia,Approved,3,0,0,1.0,1.0
691,aripiprazole,"Bipolar affective disorder, current episode manic",Approved,1,0,2,0.6666666666666666,1.0
692,aripiprazole,Schizoaffective Disorder,Terminated,0,1,2,0.3333333333333333,0.0
693,aripiprazole,Bipolar I disorder,Terminated,0,1,2,0.3333333333333333,0.0
694,aripiprazole,Bipolar Disorder,Terminated,0,0,3,0.5,0.0
695,aripiprazole,"Depressive episode, unspecified",Terminated,0,0,3,0.5,0.0
696,mitiglinide,"Diabetes Mellitus, Non-Insulin-Dependent",Approved,3,0,0,1.0,1.0
697,dasatinib,Philadelphia chromosome positive chronic myelogenous leukemia,Approved,0,0,3,0.5,1.0
698,dasatinib,Philadelphia chromosome-positive acute lymphoblastic leukemia,Approved,0,0,3,0.5,1.0
699,dasatinib,Blast Phase,Approved,0,0,3,0.5,1.0
700,dasatinib,"Leukemia, Myeloid, Chronic-Phase",Approved,0,0,3,0.5,1.0
701,dasatinib,"Leukemia, Myeloid, Accelerated Phase",Approved,0,0,3,0.5,1.0
702,dasatinib,leukemia,Terminated,0,0,3,0.5,0.0
703,dasatinib,Multiple Myeloma,Terminated,0,0,3,0.5,0.0
704,dasatinib,Malignant neoplasm of lung,Terminated,0,0,3,0.5,0.0
705,dasatinib,Non-Small Cell Lung Carcinoma,Terminated,0,0,3,0.5,0.0
706,dasatinib,Malignant neoplasm of lung,Terminated,0,0,3,0.5,0.0
707,dasatinib,Glioblastoma,Terminated,0,0,3,0.5,0.0
708,dasatinib,CNS disorder,Terminated,0,0,3,0.5,0.0
709,dasatinib,Brain Diseases,Terminated,0,0,3,0.5,0.0
710,dasatinib,Glioblastoma,Withdrawn,0,0,3,0.5,0.0
711,dasatinib,CNS disorder,Withdrawn,0,0,3,0.5,0.0
712,dasatinib,Brain Diseases,Withdrawn,0,0,3,0.5,0.0
713,lisdexamfetamine,Attention deficit hyperactivity disorder,Approved,1,0,2,0.6666666666666666,1.0
714,lisdexamfetamine,Binge eating disorder,Approved,0,0,3,0.5,1.0
715,retapamulin,Impetigo,Approved,0,0,3,0.5,1.0
716,retapamulin,Superficial bacterial infection of skin,Approved,0,0,3,0.5,1.0
717,sitagliptin,"Diabetes Mellitus, Non-Insulin-Dependent",Approved,2,0,1,0.8333333333333334,1.0
718,sitagliptin,Renal Insufficiency,Terminated,0,0,3,0.5,0.0
719,sitagliptin,Cystic Fibrosis,Terminated,0,0,3,0.5,0.0
720,decitabine,"Leukemia, Myelocytic, Acute",Approved,1,1,1,0.5,1.0
721,decitabine,adult acute myeloid leukemia with 11q23 (MLL) abnormalities,Terminated,0,2,1,0.16666666666666666,0.0
722,decitabine,adult acute myeloid leukemia with inv(16)(p13;q22),Terminated,0,2,1,0.16666666666666666,0.0
723,decitabine,adult acute myeloid leukemia with t(15;17)(q22;q12),Terminated,0,2,1,0.16666666666666666,0.0
724,decitabine,adult acute myeloid leukemia with t(16;16)(p13;q22),Terminated,0,2,1,0.16666666666666666,0.0
725,decitabine,adult acute myeloid leukemia with t(8;21)(q22;q22),Terminated,0,2,1,0.16666666666666666,0.0
726,decitabine,"Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative",Terminated,0,0,3,0.5,0.0
727,decitabine,de novo myelodysplastic syndromes,Terminated,0,1,2,0.3333333333333333,0.0
728,decitabine,"Myelodysplastic/myeloproliferative neoplasm, unclassifiable",Terminated,0,1,2,0.3333333333333333,0.0
729,decitabine,previously treated myelodysplastic syndromes,Terminated,0,1,2,0.3333333333333333,0.0
730,decitabine,recurrent adult acute myeloid leukemia,Terminated,0,2,1,0.16666666666666666,0.0
731,decitabine,secondary acute myeloid leukemia,Terminated,0,2,1,0.16666666666666666,0.0
732,decitabine,secondary myelodysplastic syndromes,Terminated,0,1,2,0.3333333333333333,0.0
733,decitabine,untreated adult acute myeloid leukemia,Terminated,0,1,2,0.3333333333333333,0.0
734,decitabine,"unspecified adult solid tumor, protocol specific",Terminated,0,2,1,0.16666666666666666,0.0
735,decitabine,Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome,Terminated,0,2,1,0.16666666666666666,0.0
736,decitabine,adult acute megakaryoblastic leukemia (M7),Terminated,0,1,2,0.3333333333333333,0.0
737,decitabine,adult acute minimally differentiated myeloid leukemia (M0),Terminated,0,1,2,0.3333333333333333,0.0
738,decitabine,adult acute monoblastic leukemia (M5a),Terminated,0,1,2,0.3333333333333333,0.0
739,decitabine,adult acute monocytic leukemia (M5b),Terminated,0,1,2,0.3333333333333333,0.0
740,decitabine,adult acute myeloblastic leukemia with maturation (M2),Terminated,0,1,2,0.3333333333333333,0.0
741,decitabine,Adult Acute Myeloid Leukemia without Maturation,Terminated,0,1,2,0.3333333333333333,0.0
742,decitabine,adult acute myeloid leukemia with 11q23 (MLL) abnormalities,Terminated,0,2,1,0.16666666666666666,0.0
743,decitabine,adult acute myeloid leukemia with inv(16)(p13;q22),Terminated,0,2,1,0.16666666666666666,0.0
744,decitabine,adult acute myeloid leukemia with t(16;16)(p13;q22),Terminated,0,2,1,0.16666666666666666,0.0
745,decitabine,adult acute myeloid leukemia with t(8;21)(q22;q22),Terminated,0,2,1,0.16666666666666666,0.0
746,decitabine,adult acute myelomonocytic leukemia (M4),Terminated,0,1,2,0.3333333333333333,0.0
747,decitabine,adult erythroleukemia (M6a),Terminated,0,1,2,0.3333333333333333,0.0
748,decitabine,adult pure erythroid leukemia (M6b),Terminated,0,1,2,0.3333333333333333,0.0
749,decitabine,secondary acute myeloid leukemia,Terminated,0,2,1,0.16666666666666666,0.0
750,decitabine,untreated adult acute myeloid leukemia,Terminated,0,1,2,0.3333333333333333,0.0
751,posaconazole,Aspergillosis,Approved,1,0,2,0.6666666666666666,1.0
752,posaconazole,Fusariosis,Approved,1,0,2,0.6666666666666666,1.0
753,posaconazole,Chromoblastomycosis,Approved,0,0,3,0.5,1.0
754,posaconazole,Mycetoma,Approved,0,0,3,0.5,1.0
755,posaconazole,Coccidioidomycosis,Approved,0,0,3,0.5,1.0
756,posaconazole,Candidiasis,Approved,0,0,3,0.5,1.0
757,darunavir,HIV Infections,Approved,3,0,0,1.0,1.0
758,telbivudine,"Hepatitis B, Chronic",Approved,1,0,2,0.6666666666666666,1.0
759,paliperidone,Schizoaffective Disorder,Approved,0,1,2,0.3333333333333333,1.0
760,paliperidone,Schizophrenia,Approved,2,0,1,0.8333333333333334,1.0
761,paliperidone,Psychotic Disorders,Approved,0,0,3,0.5,1.0
762,sunitinib,Gastrointestinal Stromal Tumors,Approved,0,0,3,0.5,1.0
763,sunitinib,Renal Cell Carcinoma,Approved,0,0,3,0.5,1.0
764,sunitinib,Acute Undifferentiated Leukemia,Terminated,0,0,3,0.5,0.0
765,sunitinib,adult acute lymphoblastic leukemia in remission,Terminated,0,0,3,0.5,0.0
766,sunitinib,adult acute myeloid leukemia in remission,Terminated,0,0,3,0.5,0.0
767,sunitinib,adult acute myeloid leukemia with 11q23 (MLL) abnormalities,Terminated,0,0,3,0.5,0.0
768,sunitinib,adult acute myeloid leukemia with inv(16)(p13;q22),Terminated,0,0,3,0.5,0.0
769,sunitinib,adult acute myeloid leukemia with t(15;17)(q22;q12),Terminated,0,0,3,0.5,0.0
770,sunitinib,adult acute myeloid leukemia with t(16;16)(p13;q22),Terminated,0,0,3,0.5,0.0
771,sunitinib,adult acute myeloid leukemia with t(8;21)(q22;q22),Terminated,0,0,3,0.5,0.0
772,sunitinib,"Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative",Terminated,0,0,3,0.5,0.0
773,sunitinib,"Leukemia, Myelomonocytic, Chronic",Terminated,0,0,3,0.5,0.0
774,sunitinib,"Leukemia, Mast-Cell",Terminated,0,0,3,0.5,0.0
775,sunitinib,meningeal chronic myelogenous leukemia,Terminated,0,0,3,0.5,0.0
776,sunitinib,Primary Myelofibrosis,Terminated,0,0,3,0.5,0.0
777,sunitinib,"progressive hairy cell leukemia, initial treatment",Terminated,0,0,3,0.5,0.0
778,sunitinib,Prolymphocytic Leukemia,Terminated,0,0,3,0.5,0.0
779,sunitinib,recurrent adult acute lymphoblastic leukemia,Terminated,0,0,3,0.5,0.0
780,sunitinib,recurrent adult acute myeloid leukemia,Terminated,0,0,3,0.5,0.0
781,sunitinib,Chronic lymphocytic leukaemia refractory,Terminated,0,0,3,0.5,0.0
782,sunitinib,Hairy cell leukaemia recurrent,Terminated,0,0,3,0.5,0.0
783,sunitinib,chronic myelogenous leukemia in relapse,Terminated,0,0,3,0.5,0.0
784,sunitinib,secondary acute myeloid leukemia,Terminated,0,0,3,0.5,0.0
785,sunitinib,Chronic lymphocytic leukaemia stage 1,Terminated,0,0,3,0.5,0.0
786,sunitinib,Chronic lymphocytic leukaemia stage 2,Terminated,0,0,3,0.5,0.0
787,sunitinib,Chronic lymphocytic leukaemia stage 3,Terminated,0,0,3,0.5,0.0
788,sunitinib,Chronic lymphocytic leukaemia stage 4,Terminated,0,0,3,0.5,0.0
789,sunitinib,T-Cell Large Granular Lymphocyte Leukemia,Terminated,0,0,3,0.5,0.0
790,sunitinib,untreated adult acute lymphoblastic leukemia,Terminated,0,0,3,0.5,0.0
791,sunitinib,untreated adult acute myeloid leukemia,Terminated,0,0,3,0.5,0.0
792,sunitinib,untreated hairy cell leukemia,Terminated,0,0,3,0.5,0.0
793,sunitinib,Non-Small Cell Lung Carcinoma,Terminated,0,0,3,0.5,0.0
794,sunitinib,Pancreatic Endocrine Carcinoma,Terminated,0,0,3,0.5,0.0
795,sunitinib,Pancreatic carcinoma,Terminated,0,0,3,0.5,0.0
796,sunitinib,Recurrent disease,Terminated,0,0,3,0.5,0.0
797,sunitinib,Kaposi's sarcoma classical type,Withdrawn,0,0,3,0.5,0.0
798,sunitinib,Adenocarcinoma of prostate,Terminated,0,0,3,0.5,0.0
799,sunitinib,Prostate cancer recurrent,Terminated,0,0,3,0.5,0.0
800,sunitinib,metastatic squamous neck cancer with occult primary squamous cell carcinoma,Terminated,0,0,3,0.5,0.0
801,sunitinib,recurrent metastatic squamous neck cancer with occult primary,Terminated,0,0,3,0.5,0.0
802,sunitinib,Recurrent Salivary Gland Cancer,Terminated,0,0,3,0.5,0.0
803,sunitinib,Squamous cell carcinoma of the hypopharynx recurrent,Terminated,0,0,3,0.5,0.0
804,sunitinib,Laryngeal squamous cell carcinoma recurrent,Terminated,0,0,3,0.5,0.0
805,sunitinib,recurrent squamous cell carcinoma of the lip and oral cavity,Terminated,0,0,3,0.5,0.0
806,sunitinib,Nasopharyngeal squamous cell carcinoma recurrent,Terminated,0,0,3,0.5,0.0
807,sunitinib,Oropharyngeal squamous cell carcinoma recurrent,Terminated,0,0,3,0.5,0.0
808,sunitinib,recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity,Terminated,0,0,3,0.5,0.0
809,sunitinib,Laryngeal verrucous carcinoma recurrent,Terminated,0,0,3,0.5,0.0
810,sunitinib,Verrucous carcinoma of the oral cavity recurrent,Terminated,0,0,3,0.5,0.0
811,sunitinib,squamous cell carcinoma of salivary gland,Terminated,0,0,3,0.5,0.0
812,sunitinib,Salivary gland cancer stage III,Terminated,0,0,3,0.5,0.0
813,sunitinib,Squamous cell carcinoma of the hypopharynx stage III,Terminated,0,0,3,0.5,0.0
814,sunitinib,Laryngeal squamous cell carcinoma stage III,Terminated,0,0,3,0.5,0.0
815,sunitinib,stage III squamous cell carcinoma of the lip and oral cavity,Terminated,0,0,3,0.5,0.0
816,sunitinib,Nasopharyngeal squamous cell carcinoma stage III,Terminated,0,0,3,0.5,0.0
817,sunitinib,Oropharyngeal squamous cell carcinoma stage III,Terminated,0,0,3,0.5,0.0
818,sunitinib,stage III squamous cell carcinoma of the paranasal sinus and nasal cavity,Terminated,0,0,3,0.5,0.0
819,sunitinib,Laryngeal verrucous carcinoma stage III,Terminated,0,0,3,0.5,0.0
820,sunitinib,Verrucous carcinoma of the oral cavity stage III,Terminated,0,0,3,0.5,0.0
821,sunitinib,Salivary gland cancer stage IV,Terminated,0,0,3,0.5,0.0
822,sunitinib,Squamous cell carcinoma of the hypopharynx stage IV,Terminated,0,0,3,0.5,0.0
823,sunitinib,Laryngeal squamous cell carcinoma stage IV,Terminated,0,0,3,0.5,0.0
824,sunitinib,stage IV squamous cell carcinoma of the lip and oral cavity,Terminated,0,0,3,0.5,0.0
825,sunitinib,Nasopharyngeal squamous cell carcinoma stage IV,Terminated,0,0,3,0.5,0.0
826,sunitinib,stage IV squamous cell carcinoma of the oropharynx,Terminated,0,0,3,0.5,0.0
827,sunitinib,stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity,Terminated,0,0,3,0.5,0.0
828,sunitinib,Laryngeal verrucous carcinoma stage IV,Terminated,0,0,3,0.5,0.0
829,sunitinib,Verrucous carcinoma of the oral cavity stage IV,Terminated,0,0,3,0.5,0.0
830,sunitinib,untreated metastatic squamous neck cancer with occult primary,Terminated,0,0,3,0.5,0.0
831,sunitinib,cognitive/functional effects,Terminated,0,0,3,0.5,0.0
832,sunitinib,"unspecified adult solid tumor, protocol specific",Terminated,0,0,3,0.5,0.0
833,sunitinib,Malignant neoplasm of lung,Terminated,0,0,3,0.5,0.0
834,sunitinib,Neuroendocrine Tumors,Terminated,0,0,3,0.5,0.0
835,sunitinib,advanced disease,Terminated,0,0,3,0.5,0.0
836,sunitinib,Plexiform Neurofibroma,Suspended,0,0,3,0.5,0.0
837,arformoterol,Chronic Obstructive Airway Disease,Approved,0,0,3,0.5,1.0
838,arformoterol,"Bronchitis, Chronic",Approved,0,0,3,0.5,1.0
839,arformoterol,Pulmonary Emphysema,Approved,0,0,3,0.5,1.0
840,nelarabine,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,Approved,0,0,3,0.5,1.0
841,nelarabine,Precursor T-cell lymphoblastic lymphoma,Approved,0,0,3,0.5,1.0
842,lumiracoxib,Degenerative polyarthritis,Approved,1,0,2,0.6666666666666666,1.0
843,lumiracoxib,"Kidney Failure, Chronic",Terminated,0,0,3,0.5,0.0
844,fosamprenavir,HIV Infections,Approved,3,0,0,1.0,1.0
845,rasagiline,Parkinson Disease,Approved,3,0,0,1.0,1.0
846,rasagiline,Progressive supranuclear palsy,Terminated,0,0,3,0.5,0.0
847,neostigmine,Myasthenia Gravis,Approved,0,0,3,0.5,1.0
848,neostigmine,Urinary Retention,Approved,0,0,3,0.5,1.0
849,tiotropium,"Bronchitis, Chronic",Approved,0,0,3,0.5,1.0
850,tiotropium,Pulmonary Emphysema,Approved,0,0,3,0.5,1.0
851,tiotropium,Asthma,Approved,0,0,3,0.5,1.0
852,tiotropium,Chronic Obstructive Airway Disease,Withdrawn,0,0,3,0.5,0.0
853,pranlukast,Allergic rhinitis (disorder),Approved,0,0,3,0.5,1.0
854,pranlukast,Asthma,Approved,3,0,0,1.0,1.0
855,phenazopyridine,Dysuria,Approved,1,0,2,0.6666666666666666,1.0
856,solifenacin,Bladder muscle dysfunction - overactive,Approved,0,0,3,0.5,1.0
857,solifenacin,Urgency of micturition,Approved,1,0,2,0.6666666666666666,1.0
858,solifenacin,Increased frequency of micturition,Approved,1,0,2,0.6666666666666666,1.0
859,solifenacin,Urge Incontinence,Approved,0,0,3,0.5,1.0
860,lopinavir,HIV Infections,Approved,0,0,3,0.5,1.0
861,lopinavir,Human immunodeficiency virus I infection,Terminated,0,0,3,0.5,0.0
862,deferasirox,Chronic iron overload,Approved,1,0,2,0.6666666666666666,1.0
863,deferasirox,beta Thalassemia,Approved,0,0,3,0.5,1.0
864,deferasirox,Iron Overload,Withdrawn,0,0,3,0.5,0.0
865,deferasirox,Iron Metabolism Disorders,Withdrawn,0,0,3,0.5,0.0
866,roflumilast,Severe chronic obstructive pulmonary disease,Approved,0,0,3,0.5,1.0
867,vorinostat,"Lymphoma, T-Cell, Cutaneous",Approved,0,0,3,0.5,1.0
868,vorinostat,Multiple Myeloma,Terminated,0,0,3,0.5,0.0
869,vorinostat,adult acute megakaryoblastic leukemia (M7),Terminated,0,0,3,0.5,0.0
870,vorinostat,adult acute minimally differentiated myeloid leukemia (M0),Terminated,0,0,3,0.5,0.0
871,vorinostat,adult acute monoblastic leukemia (M5a),Terminated,0,0,3,0.5,0.0
872,vorinostat,adult acute monocytic leukemia (M5b),Terminated,0,0,3,0.5,0.0
873,vorinostat,adult acute myeloblastic leukemia with maturation (M2),Terminated,0,0,3,0.5,0.0
874,vorinostat,Adult Acute Myeloid Leukemia without Maturation,Terminated,0,0,3,0.5,0.0
875,vorinostat,adult acute myeloid leukemia with 11q23 (MLL) abnormalities,Terminated,0,0,3,0.5,0.0
876,vorinostat,adult acute myeloid leukemia with inv(16)(p13;q22),Terminated,0,0,3,0.5,0.0
877,vorinostat,adult acute myeloid leukemia with t(16;16)(p13;q22),Terminated,0,0,3,0.5,0.0
878,vorinostat,adult acute myeloid leukemia with t(8;21)(q22;q22),Terminated,0,0,3,0.5,0.0
879,vorinostat,adult acute myelomonocytic leukemia (M4),Terminated,0,0,3,0.5,0.0
880,vorinostat,adult erythroleukemia (M6a),Terminated,0,0,3,0.5,0.0
881,vorinostat,adult pure erythroid leukemia (M6b),Terminated,0,0,3,0.5,0.0
882,vorinostat,untreated adult acute myeloid leukemia,Terminated,0,0,3,0.5,0.0
883,vorinostat,Multiple Myeloma,Terminated,0,0,3,0.5,0.0
884,vorinostat,ovarian neoplasm,Terminated,0,1,2,0.3333333333333333,0.0
885,vorinostat,Neoplasm Metastasis,Terminated,0,0,3,0.5,0.0
886,vorinostat,adult anaplastic astrocytoma,Terminated,0,0,3,0.5,0.0
887,vorinostat,adult anaplastic oligodendroglioma,Terminated,0,0,3,0.5,0.0
888,vorinostat,adult giant cell glioblastoma,Terminated,0,0,3,0.5,0.0
889,vorinostat,adult glioblastoma,Terminated,0,0,3,0.5,0.0
890,vorinostat,adult gliosarcoma,Terminated,0,0,3,0.5,0.0
891,vorinostat,Adult Mixed Glioma,Terminated,0,0,3,0.5,0.0
892,vorinostat,"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse",Terminated,0,0,3,0.5,0.0
893,vorinostat,Multiple Myeloma,Withdrawn,0,0,3,0.5,0.0
894,vorinostat,Multiple Myeloma,Withdrawn,0,0,3,0.5,0.0
895,ixabepilone,Breast Carcinoma,Approved,2,0,1,0.8333333333333334,1.0
896,ixabepilone,Carcinoma breast stage IV,Approved,1,0,2,0.6666666666666666,1.0
897,dronedarone,Paroxysmal atrial fibrillation,Approved,1,0,2,0.6666666666666666,1.0
898,nebivolol,Hypertensive disease,Approved,2,0,1,0.8333333333333334,1.0
899,homoharringtonine,"Myeloid Leukemia, Chronic",Approved,0,0,3,0.5,1.0
900,homoharringtonine,leukemia,Withdrawn,0,0,3,0.5,0.0
901,homoharringtonine,Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome,Terminated,0,0,3,0.5,0.0
902,homoharringtonine,adult acute megakaryoblastic leukemia (M7),Terminated,0,0,3,0.5,0.0
903,homoharringtonine,adult acute minimally differentiated myeloid leukemia (M0),Terminated,0,0,3,0.5,0.0
904,homoharringtonine,adult acute monoblastic leukemia (M5a),Terminated,0,0,3,0.5,0.0
905,homoharringtonine,adult acute monocytic leukemia (M5b),Terminated,0,0,3,0.5,0.0
906,homoharringtonine,adult acute myeloblastic leukemia with maturation (M2),Terminated,0,0,3,0.5,0.0
907,homoharringtonine,Adult Acute Myeloid Leukemia without Maturation,Terminated,0,0,3,0.5,0.0
908,homoharringtonine,adult acute myeloid leukemia with 11q23 (MLL) abnormalities,Terminated,0,0,3,0.5,0.0
909,homoharringtonine,adult acute myeloid leukemia with inv(16)(p13;q22),Terminated,0,0,3,0.5,0.0
910,homoharringtonine,adult acute myeloid leukemia with t(16;16)(p13;q22),Terminated,0,0,3,0.5,0.0
911,homoharringtonine,adult acute myeloid leukemia with t(8;21)(q22;q22),Terminated,0,0,3,0.5,0.0
912,homoharringtonine,adult acute myelomonocytic leukemia (M4),Terminated,0,0,3,0.5,0.0
913,homoharringtonine,adult erythroleukemia (M6a),Terminated,0,0,3,0.5,0.0
914,homoharringtonine,adult pure erythroid leukemia (M6b),Terminated,0,0,3,0.5,0.0
915,homoharringtonine,secondary acute myeloid leukemia,Terminated,0,0,3,0.5,0.0
916,homoharringtonine,untreated adult acute myeloid leukemia,Terminated,0,0,3,0.5,0.0
917,nilotinib,"Leukemia, Myeloid, Accelerated Phase",Approved,0,0,3,0.5,1.0
918,nilotinib,Philadelphia chromosome positive chronic myelogenous leukemia,Approved,0,0,3,0.5,1.0
919,nilotinib,"Leukemia, Myeloid, Chronic-Phase",Approved,0,0,3,0.5,1.0
920,vildagliptin,"Diabetes Mellitus, Non-Insulin-Dependent",Approved,3,0,0,1.0,1.0
921,bepotastine,Allergic Conjunctivitis,Approved,0,0,3,0.5,1.0
922,milnacipran,Fibromyalgia,Approved,0,0,3,0.5,1.0
923,milnacipran,Primary fibromyalgia syndrome,Terminated,0,0,3,0.5,0.0
924,milnacipran,"Fibromyalgia, Primary",Terminated,0,0,3,0.5,0.0
925,milnacipran,Irritable Bowel Syndrome,Terminated,0,0,3,0.5,0.0
926,clevidipine,Hypertensive disease,Approved,2,0,1,0.8333333333333334,1.0
927,ospemifene,Dyspareunia,Approved,0,0,3,0.5,1.0
928,tamibarotene,Acute Promyelocytic Leukemia,Approved,0,0,3,0.5,1.0
929,iloperidone,Schizophrenia,Approved,3,0,0,1.0,1.0
930,lofexidine,Opioid withdrawal,Approved,1,0,2,0.6666666666666666,1.0
931,rotigotine,Restless Legs Syndrome,Approved,1,0,2,0.6666666666666666,1.0
932,rotigotine,Parkinson Disease,Approved,2,0,1,0.8333333333333334,1.0
933,vandetanib,Malignant epithelial neoplasm of thyroid,Approved,0,0,3,0.5,1.0
934,abiraterone,Malignant neoplasm of prostate,Approved,0,0,3,0.5,1.0
935,rimonabant,Obesity,Approved,3,0,0,1.0,1.0
936,rimonabant,Microalbuminuria,Terminated,0,0,3,0.5,0.0
937,rimonabant,Dyslipidemias,Terminated,0,0,3,0.5,0.0
938,rufinamide,Lennox-Gastaut syndrome,Approved,2,0,1,0.8333333333333334,1.0
939,alogliptin,"Diabetes Mellitus, Non-Insulin-Dependent",Approved,3,0,0,1.0,1.0
940,tapentadol,Pain,Approved,2,0,1,0.8333333333333334,1.0
941,silodosin,Prostatic Hypertrophy,Approved,2,0,1,0.8333333333333334,1.0
942,prasugrel,Acute Coronary Syndrome,Approved,2,0,1,0.8333333333333334,1.0
943,prasugrel,ST segment elevation myocardial infarction,Terminated,0,0,3,0.5,0.0
944,eltrombopag,Chronic idiopathic thrombocytopenic purpura,Approved,0,0,3,0.5,1.0
945,tolvaptan,Inappropriate ADH Syndrome,Approved,0,0,3,0.5,1.0
946,tolvaptan,Hyponatremia,Approved,0,0,3,0.5,1.0
947,tolvaptan,"Polycystic Kidney, Autosomal Dominant",Approved,0,0,3,0.5,1.0
948,asenapine,Schizophrenia,Approved,2,1,0,0.6666666666666666,1.0
949,asenapine,Mixed bipolar I disorder,Approved,0,0,3,0.5,1.0
950,asenapine,"Bipolar affective disorder, current episode manic",Approved,0,0,3,0.5,1.0
951,asenapine,Stuttering,Suspended,0,0,3,0.5,0.0
952,avanafil,Erectile dysfunction,Approved,1,0,2,0.6666666666666666,1.0
953,droxidopa,Parkinson Disease,Approved,2,0,1,0.8333333333333334,1.0
954,droxidopa,"orthostatic; hypotension, neurogenic",Terminated,0,1,2,0.3333333333333333,0.0
955,droxidopa,Chronic Fatigue Syndrome,Terminated,0,1,2,0.3333333333333333,0.0
956,droxidopa,"Gait Disorders, Neurologic",Withdrawn,0,1,2,0.3333333333333333,0.0
957,droxidopa,Pure Autonomic Failure,Terminated,0,1,2,0.3333333333333333,0.0
958,droxidopa,dopamine beta hydroxylase deficiency,Terminated,0,1,2,0.3333333333333333,0.0
959,udenafil,Erectile dysfunction,Approved,1,0,2,0.6666666666666666,1.0
960,udenafil,"Heart Failure, Systolic",Terminated,0,0,3,0.5,0.0
961,sitaxentan,Pulmonary arterial hypertension,Approved,0,0,3,0.5,1.0
962,alvimopan,Postoperative ileus,Approved,0,0,3,0.5,1.0
963,saxagliptin,"Diabetes Mellitus, Non-Insulin-Dependent",Approved,3,0,0,1.0,1.0
964,pazopanib,Renal Cell Carcinoma,Approved,0,0,3,0.5,1.0
965,pazopanib,Sarcoma,Approved,0,0,3,0.5,1.0
966,agomelatine,Major Depressive Disorder,Approved,1,0,2,0.6666666666666666,1.0
967,apixaban,Arterial embolus and thrombosis,Approved,0,0,3,0.5,1.0
968,bosutinib,"Leukemia, Myeloid, Accelerated Phase",Approved,0,0,3,0.5,1.0
969,bosutinib,Blast Phase,Approved,0,0,3,0.5,1.0
970,dalfampridine,Multiple Sclerosis,Approved,0,0,3,0.5,1.0
971,vilazodone,Major Depressive Disorder,Approved,1,0,2,0.6666666666666666,1.0
972,desvenlafaxine,Major Depressive Disorder,Approved,2,0,1,0.8333333333333334,1.0
973,dexmethylphenidate,Attention deficit hyperactivity disorder,Approved,1,0,2,0.6666666666666666,1.0
974,fesoterodine,Increased frequency of micturition,Approved,2,0,1,0.8333333333333334,1.0
975,fesoterodine,Bladder muscle dysfunction - overactive,Approved,1,0,2,0.6666666666666666,1.0
976,fesoterodine,Urge Incontinence,Approved,1,0,2,0.6666666666666666,1.0
977,fesoterodine,Urgency of micturition,Approved,2,0,1,0.8333333333333334,1.0
978,lumefantrine,"Malaria, Falciparum",Approved,0,0,3,0.5,1.0
979,fosaprepitant,Chemotherapy-induced nausea and vomiting,Approved,0,0,3,0.5,1.0
980,fosaprepitant,Nausea,Suspended,0,0,3,0.5,0.0
981,fosaprepitant,Vomiting,Suspended,0,0,3,0.5,0.0
982,alcaftadine,Allergic Conjunctivitis,Approved,3,0,0,1.0,1.0
983,besifloxacin,Bacterial conjunctivitis,Approved,3,0,0,1.0,1.0
984,methylnaltrexone,Drug-induced constipation,Approved,0,0,3,0.5,1.0
985,methylnaltrexone,Gastroparesis,Terminated,0,0,3,0.5,0.0
986,plerixafor,Multiple Myeloma,Approved,1,0,2,0.6666666666666666,1.0
987,polidocanol,Varicosity,Approved,0,0,3,0.5,1.0
988,pralatrexate,Peripheral T-Cell Lymphoma,Approved,0,1,2,0.3333333333333333,1.0
989,lurasidone,Schizophrenia,Approved,2,0,1,0.8333333333333334,1.0
990,lurasidone,"Depression, Bipolar",Approved,0,0,3,0.5,1.0
991,ticagrelor,Acute Coronary Syndrome,Approved,1,0,2,0.6666666666666666,1.0
992,ticagrelor,Peripheral Vascular Diseases,Approved,0,0,3,0.5,1.0
993,ticagrelor,ST segment elevation myocardial infarction,Terminated,0,0,3,0.5,0.0
994,tafluprost,Ocular Hypertension,Approved,3,0,0,1.0,1.0
995,tafluprost,"Glaucoma, Open-Angle",Approved,3,0,0,1.0,1.0
996,ivacaftor,Pulmonary Cystic Fibrosis,Approved,0,0,3,0.5,1.0
997,deferiprone,beta Thalassemia,Approved,0,0,3,0.5,1.0
998,deferiprone,Iron Overload,Approved,0,0,3,0.5,1.0
999,vismodegib,Basal cell carcinoma,Approved,0,0,3,0.5,1.0
1000,pitavastatin,"Hyperlipidemia, Familial Combined",Approved,3,0,0,1.0,1.0
1001,pitavastatin,Hypercholesterolemia,Approved,3,0,0,1.0,1.0
1002,rilpivirine,HIV Infections,Approved,3,0,0,1.0,1.0
1003,fingolimod,"Multiple Sclerosis, Relapsing-Remitting",Approved,0,0,3,0.5,1.0
1004,boceprevir,"Hepatitis C, Chronic",Approved,0,0,3,0.5,1.0
1005,ruxolitinib,Myeloproliferative disease,Approved,0,0,3,0.5,1.0
1006,ruxolitinib,Myelofibrosis,Approved,0,0,3,0.5,1.0
1007,linagliptin,"Diabetes Mellitus, Non-Insulin-Dependent",Approved,3,0,0,1.0,1.0
1008,linagliptin,Vascular inflammations,Terminated,0,0,3,0.5,0.0
1009,carfilzomib,Multiple Myeloma,Approved,0,1,2,0.3333333333333333,1.0
1010,mirabegron,Bladder muscle dysfunction - overactive,Approved,2,0,1,0.8333333333333334,1.0
1011,regorafenib,Metastasis from malignant tumor of colon,Approved,0,0,3,0.5,1.0
1012,regorafenib,Gastrointestinal Stromal Tumors,Approved,0,0,3,0.5,1.0
1013,aclidinium,Chronic Obstructive Airway Disease,Approved,0,0,3,0.5,1.0
1014,enzalutamide,Malignant neoplasm of prostate,Approved,0,0,3,0.5,1.0
1015,ponatinib,"Myeloid Leukemia, Chronic",Approved,0,0,3,0.5,1.0
1016,ponatinib,Philadelphia chromosome-positive acute lymphoblastic leukemia,Approved,0,0,3,0.5,1.0
1017,ponatinib,Thyroid Neoplasm,Terminated,0,0,3,0.5,0.0
1018,bedaquiline,"Tuberculosis, Pulmonary",Approved,3,0,0,1.0,1.0
1019,bedaquiline,"Tuberculosis, Drug-Resistant",Approved,0,0,3,0.5,1.0
1020,canagliflozin,"Diabetes Mellitus, Non-Insulin-Dependent",Approved,3,0,0,1.0,1.0
1021,pomalidomide,Multiple Myeloma,Approved,1,0,2,0.6666666666666666,1.0
1022,trametinib,"Malignant melanoma, metastatic",Approved,0,0,3,0.5,1.0
1023,trametinib,recurrent adult acute myeloid leukemia,Suspended,0,0,3,0.5,0.0
1024,trametinib,untreated adult acute myeloid leukemia,Suspended,0,0,3,0.5,0.0
1025,trametinib,malignant neoplasm of large intestine stage IIIc,Suspended,0,0,3,0.5,0.0
1026,trametinib,Melanoma recurrent,Suspended,0,0,3,0.5,0.0
1027,trametinib,Stage IIIC Skin Melanoma,Suspended,0,0,3,0.5,0.0
1028,trametinib,Colorectal cancer recurrent,Suspended,0,0,3,0.5,0.0
1029,trametinib,Pancreatic carcinoma stage III,Suspended,0,0,3,0.5,0.0
1030,trametinib,Stage IIIA Colorectal Cancer,Suspended,0,0,3,0.5,0.0
1031,trametinib,Stage IIIB Colorectal Cancer,Suspended,0,0,3,0.5,0.0
1032,trametinib,Stage IIIC Colorectal Cancer,Suspended,0,0,3,0.5,0.0
1033,trametinib,Stage IV Pancreatic Cancer,Suspended,0,0,3,0.5,0.0
1034,trametinib,Stage IVA Colorectal Cancer,Suspended,0,0,3,0.5,0.0
1035,trametinib,Stage IVB Colorectal Cancer,Suspended,0,0,3,0.5,0.0
1036,trametinib,hepatic complications,Suspended,0,0,3,0.5,0.0
1037,trametinib,Papillary serous cystadenocarcinoma,Suspended,0,0,3,0.5,0.0
1038,trametinib,Ovarian Serous Adenocarcinoma,Suspended,0,0,3,0.5,0.0
1039,trametinib,Primary Peritoneal Serous Adenocarcinoma,Suspended,0,0,3,0.5,0.0
1040,trametinib,Recurrent Primary Peritoneal Carcinoma,Suspended,0,0,3,0.5,0.0
1041,trametinib,Poorly Differentiated Thyroid Carcinoma,Suspended,0,0,3,0.5,0.0
1042,trametinib,Stage IVA Thyroid Gland Follicular Carcinoma,Suspended,0,0,3,0.5,0.0
1043,trametinib,Stage IVA Thyroid Gland Papillary Carcinoma,Suspended,0,0,3,0.5,0.0
1044,trametinib,Stage IVB Thyroid Gland Follicular Carcinoma,Suspended,0,0,3,0.5,0.0
1045,trametinib,Stage IVB Thyroid Gland Papillary Carcinoma,Suspended,0,0,3,0.5,0.0
1046,trametinib,Stage IVC Thyroid Gland Follicular Carcinoma,Suspended,0,0,3,0.5,0.0
1047,trametinib,Stage IVC Thyroid Gland Papillary Carcinoma,Suspended,0,0,3,0.5,0.0
1048,trametinib,Melanoma recurrent,Suspended,0,0,3,0.5,0.0
1049,trametinib,Stage IIIA Skin Melanoma,Suspended,0,0,3,0.5,0.0
1050,trametinib,Stage IIIB Skin Melanoma,Suspended,0,0,3,0.5,0.0
1051,trametinib,Stage IIIC Skin Melanoma,Suspended,0,0,3,0.5,0.0
1052,dabrafenib,"Malignant melanoma, metastatic",Approved,0,0,3,0.5,1.0
1053,dabrafenib,malignant neoplasm of large intestine stage IIIc,Suspended,0,0,3,0.5,0.0
1054,dabrafenib,Melanoma recurrent,Suspended,0,0,3,0.5,0.0
1055,dabrafenib,Stage IIIC Skin Melanoma,Suspended,0,0,3,0.5,0.0
1056,dabrafenib,Melanoma recurrent,Suspended,0,0,3,0.5,0.0
1057,dabrafenib,Stage IIIA Skin Melanoma,Suspended,0,0,3,0.5,0.0
1058,dabrafenib,Stage IIIB Skin Melanoma,Suspended,0,0,3,0.5,0.0
1059,dabrafenib,Stage IIIC Skin Melanoma,Suspended,0,0,3,0.5,0.0
1060,afatinib,Epidermal growth factor receptor positive non-small cell lung cancer,Approved,0,0,3,0.5,1.0
1061,levomilnacipran,Major Depressive Disorder,Approved,0,0,3,0.5,1.0
1062,aliskiren,Hypertensive disease,Approved,3,0,0,1.0,1.0
1063,memantine,Schizophrenia,Terminated,0,1,2,0.3333333333333333,0.0
1064,memantine,Chronic schizophrenia,Terminated,0,0,3,0.5,0.0
1065,memantine,Glioblastoma,Terminated,0,0,3,0.5,0.0
1066,memantine,Asperger Syndrome,Terminated,0,0,3,0.5,0.0
1067,fulvestrant,Malignant epithelial neoplasm of female breast,Terminated,1,0,2,0.6666666666666666,0.0
1068,azacitidine,leukemia,Terminated,0,3,0,0.0,0.0
1069,azacitidine,Chronic myeloproliferative disorder,Terminated,0,1,2,0.3333333333333333,0.0
1070,azacitidine,Myelofibrosis due to another disorder,Terminated,0,1,2,0.3333333333333333,0.0
1071,azacitidine,Multiple Myeloma,Terminated,0,1,2,0.3333333333333333,0.0
1072,azacitidine,leukemia,Terminated,0,3,0,0.0,0.0
1073,azacitidine,leukemia,Terminated,0,3,0,0.0,0.0
1074,azacitidine,"Leukemia, Myelocytic, Acute",Withdrawn,1,1,1,0.5,0.0
1075,azacitidine,adult acute basophilic leukemia,Terminated,0,1,2,0.3333333333333333,0.0
1076,azacitidine,adult acute eosinophilic leukemia,Terminated,0,1,2,0.3333333333333333,0.0
1077,azacitidine,adult acute myeloid leukemia in remission,Terminated,0,2,1,0.16666666666666666,0.0
1078,azacitidine,Adult Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11,Terminated,0,0,3,0.5,0.0
1079,azacitidine,Adult Acute Myeloid Leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1,Terminated,0,0,3,0.5,0.0
1080,azacitidine,untreated adult acute myeloid leukemia,Terminated,0,1,2,0.3333333333333333,0.0
1081,azacitidine,Adult Erythroleukemia,Terminated,0,0,3,0.5,0.0
1082,azacitidine,Adult Pure Erythroid Leukemia,Terminated,0,0,3,0.5,0.0
1083,azacitidine,Alkylating Agent-Related Acute Myeloid Leukemia,Terminated,0,0,3,0.5,0.0
1084,azacitidine,recurrent adult acute myeloid leukemia,Terminated,0,2,1,0.16666666666666666,0.0
1085,azacitidine,secondary acute myeloid leukemia,Terminated,0,2,1,0.16666666666666666,0.0
1086,azacitidine,leukemia,Terminated,0,3,0,0.0,0.0
1087,azacitidine,"Leukemia, Myelocytic, Acute",Terminated,1,1,1,0.5,0.0
1088,azacitidine,"Leukemia, Myelomonocytic, Chronic",Terminated,0,0,3,0.5,0.0
1089,azacitidine,"Leukemia, Myelocytic, Acute",Terminated,1,1,1,0.5,0.0
1090,azacitidine,Multiple Myeloma,Terminated,0,1,2,0.3333333333333333,0.0
1091,azacitidine,MYELODYSPLASTIC SYNDROME,Terminated,0,0,3,0.5,0.0
1092,valganciclovir,Cytomegalovirus Infections,Terminated,0,1,2,0.3333333333333333,0.0
1093,zonisamide,Epilepsy,Terminated,3,0,0,1.0,0.0
1094,zonisamide,Epilepsy,Terminated,3,0,0,1.0,0.0
1095,zonisamide,"Alcoholic Intoxication, Chronic",Terminated,0,0,3,0.5,0.0
1096,zonisamide,alcohol use disorder,Terminated,0,0,3,0.5,0.0
1097,zonisamide,Bipolar Disorder,Terminated,0,0,3,0.5,0.0
1098,lapatinib,Neoplasm Metastasis,Terminated,0,0,3,0.5,0.0
1099,lapatinib,melanoma,Terminated,0,0,3,0.5,0.0
1100,lapatinib,HER-2 positive breast cancer,Withdrawn,0,0,3,0.5,0.0
1101,lapatinib,Bladder cancer stage III,Terminated,0,0,3,0.5,0.0
1102,lapatinib,Adenocarcinoma Of Esophagus,Terminated,0,0,3,0.5,0.0
1103,lapatinib,Adenocarcinoma of the gastroesophageal junction,Terminated,0,0,3,0.5,0.0
1104,lapatinib,Endocrine Breast Diseases,Terminated,0,0,3,0.5,0.0
1105,lapatinib,Neoplasm Metastasis,Terminated,0,0,3,0.5,0.0
1106,lapatinib,Breast cancer recurrent,Terminated,0,0,3,0.5,0.0
1107,varenicline,Drug Dependence,Withdrawn,0,0,3,0.5,0.0
1108,varenicline,Nicotine Dependence,Terminated,1,0,2,0.6666666666666666,0.0
1109,ezogabine,Epilepsy,Terminated,0,0,3,0.5,0.0
1110,ezogabine,Epilepsy,Terminated,0,0,3,0.5,0.0
1111,ezogabine,Epilepsy,Terminated,0,0,3,0.5,0.0
1112,rivaroxaban,Heparin-induced thrombocytopenia,Terminated,0,0,3,0.5,0.0
